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ABSTRACT 
Protein folding in the endoplasmic reticulum (ER) is essential for proper cellular 
function. However, the sensitive environment in the ER can be perturbed by both 
pathological processes as well as by physiological processes such as a large biosynthetic 
load placed on the ER. ER stress is a specific type of intracellular stress caused by the 
accumulation of immature or abnormal misfolded or unfolded proteins in the ER. Simply 
defined, ER stress is a disequilibrium between ER load and folding capacity. Cells have 
an adaptive response that counteracts ER stress called the "Unfolded Protein Response” 
(UPR). The ability to adapt to physiological levels of ER stress is especially important for 
maintaining ER homeostasis in secretory cells. This also holds true for pancreatic β-cells, 
which must fold and process large amounts of the hormone insulin. 
Pancreatic β-cells minimize abnormal levels of glycemia through adaptive 
changes in the production and regulated secretion of insulin. This process is highly 
sensitive, so that small degrees of hypo- or hyperglycemia result in altered insulin 
release. The frequent fluctuation of blood glucose levels in humans requires that β-cells 
control proinsulin folding in the ER with exquisite sensitivity.  Any imbalance between 
the load of insulin translation into the ER and the actual capacity of the ER to properly 
fold and process the insulin negatively affects the homeostasis of β-cells and causes ER 
stress. 
In this dissertation, we show that Inositol Requiring 1 (IRE1), an ER-resident 
kinase/endoribonuclease and a central regulator of ER stress signaling, is essential for 
maintaining ER homeostasis in pancreatic β-cells. Importantly,  IRE1 has a crucial 
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function in the body’s normal production of insulin in response to high glucose. 
Phosphorylation and subsequent activation of IRE1 by transient exposure to high glucose 
is coupled to insulin biosynthesis, while inactivation of IRE1 by siRNA or inhibition of 
IRE1 phosphorylation abolishes insulin biosynthesis. IRE1 signaling under these 
physiological ER stress conditions utilizes a unique subset of downstream components of 
IRE1 and has a beneficial effect on pancreatic β-cell homeostasis. 
In contrast, we show that chronic exposure of β-cells to high glucose causes 
pathological levels of ER stress and hyperactivation of IRE1, leading to the degradation 
of insulin mRNA. The term “glucose toxicity” refers to impaired insulin secretion by β-
cells in response to chronic stimulation by glucose and is characterized by a sharp decline 
in insulin gene expression. However, the molecular mechanisms of glucose toxicity are 
not well understood. We show that hyperactivation of IRE1 caused by chronic high 
glucose treatment or IRE1 overexpression leads to insulin mRNA degradation in 
pancreatic β-cells.  Inhibition of IRE1 signaling using a dominant negative form of the 
protein prevents insulin mRNA degradation in β-cells.  Additionally, islets from mice 
heterozygous for IRE1 retain expression of more insulin mRNA after chronic high 
glucose treatment than do their wild-type littermates.  
This work suggests that the rapid degradation of insulin mRNA could provide 
immediate relief for the ER and free up the translocation machinery.  Thus, this 
mechanism may represent an essential element in the adaptation of β-cells to chronic 
hyperglycemia. This adaptation is crucial for the maintenance of β-cell homeostasis and 
may explain in part why the β-cells of diabetic patients with chronic hyperglycemia stop 
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producing insulin without simply undergoing apoptosis. This work implies that prolonged 
activation of IRE1 signaling is involved in the molecular mechanisms underlying glucose 
toxicity.  
This work therefore reveals two distinct activities elicited by IRE1 in pancreatic 
β-cells. IRE1 signaling activated by transient exposure to high glucose enhances 
proinsulin biosynthesis, while chronic exposure of β-cells to high glucose causes 
hyperactivation of IRE1, leading to the degradation of insulin mRNA. Physiological 
IRE1 activation by transient high glucose levels in pancreatic β cells has a beneficial 
effect on insulin biosynthesis.  However, pathological IRE1 activation by chronic high 
glucose or experimental drugs negatively affects insulin gene expression. In the future, a 
system to induce a physiological level of IRE1 activation, and/or reduce the pathological 
level of IRE1 activation could be used to enhance insulin biosynthesis and secretion in 
people with diabetes, and may lead to the development of new and more effective clinical 
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 CHAPTER I 
INTRODUCTION 
Diabetes mellitus (DM) is a group of metabolic disorders characterized by 
abnormally high blood glucose levels. This disease is reaching epidemic proportions 
worldwide with the predicted number of affected adults increasing from 135 million 
individuals in 1995 to over 300 million by 2025 [1]. About 90-95% of the diagnosed 
cases are Type 2 DM, considered a polygenic disease influenced by a number of factors 
including genetic predisposition, aging, and behavioral issues. Through lifelong vascular 
complications, diabetes leads to high rates of heart attack, stroke, kidney failure, 
blindness, and amputations. In the United States, diabetes accounts for over 130 billion 
dollars of health care costs per year, and is the fifth leading cause of death [2]. 
 The pathogenesis of diabetes involves defective insulin signaling and β-cell 
dysfunction. Insulin, a hormone produced in the β-cells of the pancreas, is essential for 
lowering blood glucose levels. Pancreatic β-cells’ main function is the production, 
storage, and regulated secretion of insulin. This process is highly sensitive, so that only 
small changes in blood glucose concentrations result in altered insulin release. Thus, 
when blood glucose levels are elevated, such as after a meal, β-cells secrete insulin into 
the bloodstream where it is transported to the liver, adipose tissue and skeletal muscle. At 
these target tissues, insulin stimulates glucose uptake into the cells where the glucose is 
then metabolized to produce energy for cellular functions or converted and stored as 
glycogen or triglycerides. Under normal conditions, the β-cell always maintains a readily 
available pool of insulin that can be rapidly secreted in response to changes in blood 
 2 
glucose level.  In patients with diabetes, however, the β-cells produce little or no insulin 
(Type 1 DM), or have defects in insulin secretion (Type 2 DM). This has two negative 
implications: 1) glucose builds up to toxic levels in the blood, and 2) the cells of the 
peripheral tissues are starved of their main source of energy. 
Pancreatic β-cell dysfunction is a pathogenic component in the progression of 
both Type 1 and Type 2 DM [3, 4].  Ever since this important role was recognized, 
extensive research has been done to try to understand the unique properties of the β-cell 
and how they contribute to insulin production and secretion in response to glucose. 
Human pancreatic β-cells are found in the islets of Langerhans, specialized clusters of a 
few hundred to a few thousand endocrine cells which are anatomically and functionally 
separate from pancreatic exocrine tissue (which secretes pancreatic enzymes and fluid 
directly into ducts that drain into the duodenum). Normal individuals have about one 
million islets, which constitute 1 to 2 percent of the mass of the pancreas. The islets 
themselves are composed of several types of cells. The majority of the islet (about 80%) 
is composed of β-cells, which make up the inner core of the islet.  These cells are 
surrounded by α-cells that secrete glucagon, δ-cells that secrete somatostatin, and PP cells 
that secrete pancreatic polypeptide [5, 6]. 
In order to compensate for insulin release and maintain sufficient intracellular 
stores of insulin, β-cells must constantly adjust their rates of insulin biosynthesis. 
Biologically active insulin is first synthesized in the cytoplasm as a precursor molecule 
called preproinsulin.  Preproinsulin mRNA contains a signal peptide that directs it across 
the endoplasmic reticulum (ER) membrane through interactions between the signal 
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peptide and the signal-recognition particle.  After its cotranslational translocation into the 
ER lumen, the signal peptide is cleaved, producing proinsulin. In the lumen of the ER, 
proinsulin undergoes meticulous processing and folding so that three critical disulfide 
linkages are correctly aligned. This process is catalyzed by protein disulfide isomerase 
(PDI) , ER oxidoreductase α (ERO1α) and the molecular chaperone BiP [7, 8].  Once past 
the ER’s internal quality control system, proinsulin is transferred to the Golgi apparatus 
and packaged into secretory granules. It is inside these granules that the proinsulin is 
converted into the mature form of insulin. The granules keep insulin in crystalline form in 
an intracellular storage pool until eventually triggered to transport it to the plasma 
membrane for exocytosis. The insulin content of the β-cell stays relatively constant under 
normal conditions, striking an important balance between secretion and biosynthesis and 
ensuring a readily available, rapidly releasable pool of insulin [7].  
Signals activating glucose-stimulated proinsulin biosynthesis in response to 
glucose-stimulated insulin secretion are, unfortunately, unknown. It has been shown that 
glucose metabolism is required, but secondary signals beyond that remain to be 
determined. The proinsulin biosynthetic machinery’s response to an increase in glucose 
concentration is rapid [9] and for short term stimulation (less than 2 hours) seems to be 
regulated entirely at the translational level in that it does not alter the total amount of 
preproinsulin mRNA [10, 11]. The rapid response to glucose uses translational regulation 
of pre-existing preproinsulin mRNA.  Interestingly, the translational response of the β-
cell to increased glucose concentration seems to be specific for proinsulin 
biosynthesis[12]. General protein synthesis translation is only increased at most, two-fold 
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by high glucose concentrations, whereas glucose-induced proinsulin biosynthesis can be 
increased 15-fold above general protein synthesis [13, 14]. Thus, proinsulin translation 
accounts for the majority of protein synthesis in glucose stimulated cells. 
During longer glucose stimulation periods (greater than 4 hours) transcriptional 
upregulation of insulin has also been observed [15]. Indeed, chronic elevation of 
extracellular glucose concentrations further stimulates the biosynthesis of insulin by 
increasing expression of preproinsulin mRNA, increasing proinsulin translation and 
processing, and upregulating the capacity of the β-cell’s secretory pathway [16].  Both 
acute and chronic hyperglycemia stimulate β-cells to secrete insulin. This release of 
insulin simultaneously activates insulin biosynthesis in the ER of the β-cells. β-cells must 
therefore adapt their acute and chronic rates of insulin biosynthesis to compensate for 
insulin release. Any imbalance between the physiological load of insulin translation into 
the ER and the actual capacity of the ER to fold and process the insulin can negatively 
affect the homeostasis of β-cells and lead to ER stress [17].  
ER stress is a specific type of intracellular stress caused by misfolded or unfolded 
proteins accumulating in the ER[18, 19]. ER stress is broadly defined as any perturbation 
that compromises the protein folding functionality of the ER, including mutation of ER 
chaperones or foldases, viral infections, exposure to chemical agents, metabolic demands, 
and importantly, the normal differentiation and function of secretory cells [20, 21]. The 
ability to adapt to physiological levels of ER stress has been suggested to be especially 
important for secretory cells, because the ER is subject to greater loads of client proteins 
which must be properly folded by the protein processing machinery [17]. This holds true 
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for pancreatic β-cells, which as professional secretory cells, must fold and process large 
amounts of insulin [22]. The frequent fluctuation of blood glucose levels requires that β-
cells control insulin folding with exquisite sensitivity in order to maintain intracellular 
insulin stores. Diabetes may result when the β-cell fails to adapt to ER stress caused by 
the increased demand for insulin production imposed by high blood glucose 
concentrations. 
Cells respond to ER stress via an intracellular adaptive response called the 
unfolded protein response (UPR). In metazoans, three distinct ER-resident 
transmembrane proteins have been identified as the upstream transducers of the UPR and 
are constitutively expressed. Inositol-requiring-1 (IRE1) was the first UPR master 
regulator to be identified initially in yeast [23, 24]. The unique functions of IRE1 have 
been conserved in all eukaryotic cells, but higher eukaryotes also possess the additional 
UPR transducers protein kinase RNA (PKR)-like ER kinase (PERK), and activating 
transcription factor-6 (ATF6). Each of these three upstream transducers sense the protein 
folding status in the lumen of the ER and transmit this information across the ER 
membrane into the cytoplasm. The mechanisms of exactly how they sense the 
accumulation of unfolded proteins is still not well described, however, all three appear to 
be activated in part by the competitive titration of the ER chaperone BiP away from 
interactions with themselves in favor of binding to unfolded proteins in the lumen [25-
27]. 
The UPR utilizes three main responses to mitigate ER stress. The first is a 
transient adaptation designed to immediately reduce the protein workload of the 
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overwhelmed ER through reduction in protein synthesis and ER translocation, and an 
increase in protein degradation. The second is a longer term adaptation designed to 
increase the capacity of the ER through transcriptional upregulation of UPR target genes, 
including ones encoding chaperones, foldases, and other proteins that function as part of 
the ER protein folding machinery. The final response, apoptosis, may occur if ER 
homeostasis cannot be restored via the first two mechanisms and is presumably a 
protective response [28]. Although there appears to be much overlap in the pathways that 
contribute to the protein folding and degradation capacity of the ER during stress, each of 
the three upstream transducers of the UPR may uniquely regulate some genes and control 
some physiological responses [29, 30]. 
ATF6, an upstream ER stress transducer, is a transcription factor which is 
synthesized as an inactive molecule bound to the ER membrane by its transmembrane 
segment. Upon ER stress, BiP dissociation from ATF6 releases ATF6 from the ER 
membrane where it is then transported to the Golgi apparatus. There it is cleaved by site 1 
and site 2 proteases to release the active DNA-binding portion into the cytosol [31]. The 
active form of ATF6 then goes to the nucleus where it upregulates genes encoding ER 
chaperones including BiP, GRP94, PDI, and calreticulin [32, 33]. There are two isoforms, 
ATF6α and ATF6β. It has been recently shown that the α isoform is solely responsible 
for transcriptional induction of ER chaperones [34]. In addition to regulating this subset 
of genes in response to acute ER stress, ATF6 is also thought to augment the protective 
mechanisms upregulated by the PERK and IRE1 pathways in an effort to suppress 
apoptotic UPR signaling cascades and allow the cell to withstand chronic ER stress [30]. 
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A second ER stress transducer, PERK, is a type 1 ER resident protein that 
contains a kinase domain in the cytoplasmic portion of the protein. Under ER stress 
conditions, PERK senses the accumulation of misfolded proteins in the ER lumen and 
becomes active via BiP dissociation, which allows dimerization and trans-
autophosphorylation of PERK [35]. The activated kinase domain then phosphorylates the 
α subunit of the cytosolic eukaryotic translation initiation factor eIF2, which inhibits 
assembly of the 80S ribosome, thereby inhibiting protein synthesis [36, 37]. The result is 
a global reduction in the load of proteins entering the already overwhelmed ER.  
Additionally, PERK induced phosphorylation of eIF2α results in the selective translation 
of mRNAs responsible for normal UPR function. These mRNAs share the feature that 
they all require the ribosome to “skip” inhibitory upstream open reading frames in order 
to have their AUG codon recognized properly [38].  The best known example of this is 
the transcription factor ATF4, which is preferentially translated under ER stress 
conditions when eIF2α is phosphorylated. ATF4 also activates the transcription of genes 
important for responding to additional stresses other than ER stress, including synthesis 
of amino acids and redox balance [39, 40]. Additionally, production of the pro-apoptotic 
transcription factor CHOP/GADD153 requires PERK, eIF2α phosphorylation, and ATF4 
[41, 42]. It has been suggested that long term PERK activation may initiate apoptosis via 
CHOP induction if ER homeostasis is not restored. 
ER stress induced activation of PERK is readily reversible, as unregulated 
phosphorylation of eIF2α would be disastrous to the cell. The exact regulatory 
mechanisms and the phosphatases involved remain to be determined. However, it has 
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been shown that phosphorylated eIF2α is negatively regulated by two genes, GADD34 
and CReP, which encode the substrate targeting subunits of two independent phosphatase 
complexes that can dephosphorylate eIF2α. GADD34 is induced by the gene expression 
system initiated by eIF2α phosphorylation and so functions in a negative feedback loop 
[43]. CReP is constitutively expressed and is involved in baseline eIF2α 
dephosphorylation [44].  These proteins and perhaps others ensure that the general 
translational attenuation implemented by PERK induced eIF2α phosphorylation is lifted 
as soon as ER homeostasis is restored. 
The third and most highly conserved ER stress transducer, IRE1, is a type 1 ER 
resident transmembrane protein kinase/endoribonuclease. In the absence of ER stress, 
IRE1 exists as inactive monomers in the ER membrane.  Under ER stress conditions, 
IRE1 senses the presence of unfolded proteins in the ER lumen, which causes 
dimerization and trans-autophosphorylation of its kinase domains.  Dimerization can be 
directly triggered by the binding of unfolded proteins to the IRE1 lumenal domain, and 
may also involve the release of the chaperone, BiP, from the lumenal domain[25, 45, 46]. 
Trans-autophosphorylation of the kinase domain of IRE1 activates its RNase activity, 
whereby IRE1 initiates precise endonucleolytic cleavage of an mRNA encoding a 
transcription factor called X-box binding protein-1 (XBP-1) [47, 48].  IRE1 RNase 
activity results in the removal of a 26 nucleotide intron from XBP-1 mRNA. This unique 
cytoplasmic splicing reaction initiates a translational frameshift which produces a form of 
XBP-1 that contains a novel transcriptional activation domain.  
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Spliced XBP-1 is a transcriptional activator that plays an essential role in the 
activation of a wide variety of UPR target genes, including many genes responsible for 
ER associated degradation (ERAD) [49]. Levels of XBP-1 mRNA increase upon 
induction of the UPR and continue to go up as ER stress is reduced and IRE1 is 
inactivated. Thus, the new XBP-1 mRNA remains in its unspliced form, which is also 
translated and encodes an inhibitor of XBP-1 signaling [50]. This may serve to terminate 
signaling, either through inhibitory heterodimerization of spliced and unspliced XBP-1 
proteins, or competition for binding sites. The IRE1-XBP-1 pathway has been found to 
have a critical role in the differentiation of B lymphocytes into plasma cells [51, 52]. 
These studies suggest that IRE1-XBP-1 signaling may be required for the function and 
differentiation of cells that secrete high levels of protein. 
In metazoans, IRE1 has additional signaling activity independent of XBP-1 
splicing. If the accumulation of unfolded proteins in the ER is unable to be resolved via 
the IRE1-XBP-1 pathway, prolonged activation of IRE1 activates stress-induced Jun N-
terminal kinase (JNK), which can lead to apoptosis in some cell types [53, 54]. However, 
aside from indirect evidence for a contribution to death in severe ER-stressed cells, the 
physiological relevance of JNK activation by IRE1 remains unclear.   
Recent work in Drosophila cells has shown evidence for more widespread IRE1-
dependent degradation of ER-associated mRNAs[55]. This is an XBP-1-independent 
pathway involving specific cleavage and subsequent degradation of sets of mRNAs being 
translated on the ER membrane.  This response complements other components of the 
UPR, selectively halting protein synthesis and clearing the translocation machinery when 
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translating mRNAs are overloading the ER and causing ER stress.  It has been suggested 
that this specific mRNA degradation may result from IRE1 focusing on messages that 
present the most immediate challenge to the translocation and folding machinery [55].  
Collectively, activation of the three upstream UPR transducers, ATF6, PERK, and 
IRE1 proceeds independently in ER stressed cells, however, all three arms communicate 
extensively with one another to prevent the accumulation of unfolded proteins. The UPR 
broadly functions to increase the capacity of a cell to carry out protein secretion by 
utilizing signaling pathways that ensure that the rate of protein synthesis, folding, and 
degradation are tightly controlled. Accumulating evidence suggests that protein 
misfolding in the ER lumen and defects in UPR signaling play significant roles in the 
etiology of numerous diseases states, including neurodegenerative disorders and 
metabolic diseases like diabetes. 
Pancreatic β-cell dysfunction is a major component in the progression of both 
Type 1 and Type 2 diabetes. The relationship between ER stress and pancreatic β-cell 
dysfunction was first revealed in a rare autosomal recessive form of juvenile diabetes, 
Wolcott-Rallison syndrome. In this syndrome, mutations occur in the EIF2AK3 gene 
encoding PERK [56]. These mutations occur within the catalytic domain of PERK, and 
cause a loss of function of the kinase activity of PERK and lead to decreased 
phosphorylation of eIF2α. If a high workload is placed on the ER, eIF2α phosphorylation 
is essential in mitigating the ER stress level, thereby promoting cell survival [36]. 
Therefore, the loss of function of PERK and decreased eIF2α phosphorylation may 
directly lead to β-cell dysfunction or death. Indeed, PERK knockout mice develop 
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diabetes due to β-cell apoptosis caused by a high level of ER stress in the pancreatic islets 
[57]. In addition, when mice that have a heterozygous mutation in the phosphorylation 
site of eIF2α are fed a high-fat diet, they become obese and diabetic due to β-cell 
dysfunction [58]. Collectively, these observations strongly suggest that regulation of 
translation initiation through PERK/eIF2α is necessary for ER stress signaling to prevent 
β-cell dysfunction when the demand for insulin is increased due to a high fat diet and 
insulin resistance. These studies also imply that β-cells have a unique requirement for 
PERK regulated translation, and suggest that β-cell dysfunction and death in patients with 
Wolcott-Rallison syndrome is caused by a high level of ER stress and a defect in the 
UPR.  
The idea that, as a professional secretory cell, the β-cell is particularly vulnerable 
to ER stress, was further supported by the characterization of the Akita mouse. The Akita 
diabetes mouse model is a C57BL/6 mouse that is heterozygous for a mutation in the 
insulin 2 gene [59]. This mutation results in a tyrosine substitution for a highly conserved 
cysteine involved in the formation of one of the three critical disulfide bonds found in 
mature insulin protein. This mutation causes incorrect folding of proinsulin in the ER of 
pancreatic β-cells, and so is toxic due to the induction of the ER stress response, and thus 
leads to diabetes [60, 61]. The mutant protein cannot be processed and secreted normally 
and is retained in the ER. The ER in Akita β-cells has been shown to be distended and the 
UPR response genes BiP and CHOP are upregulated. Deletion of the CHOP gene in these 
mice delayed the onset of both hyperglycemia and β-cell destruction. Thus, studies of the 
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Akita diabetes model support the hypothesis that severe ER stress causes β-cell death 
[62]. 
More recently, mutations in the human insulin gene INS have been linked to 
neonatal diabetes [63, 64]. The mutations are in critical regions of the preproinsulin 
molecule, and are predicted to prevent normal folding and progression of proinsulin in 
the insulin secretory pathway. The abnormally folded proinsulin may induce the UPR and 
undergo degradation in the ER, causing severe ER stress, and potentially, β-cell death by 
apoptosis. One of the human mutations reported in this study is identical to that in the 
Akita mouse. The identification of insulin mutations as a cause of neonatal diabetes 
further supports the idea that insulin misfolding in the ER can cause ER stress and lead to 
β-cell death. 
ER stress is also involved in β-cell death in patients with Wolfram syndrome. In 
1938, Wolfram and Wagener provided the first report of Wolfram Syndrome when they 
analyzed four siblings with the combination of juvenile diabetes and optic atrophy [65]. 
Although patients with Wolfram syndrome are not generally obese, the β-cells in their 
pancreatic islets are selectively destroyed [66]. Families that exhibit Wolfram syndrome 
share mutations in a gene encoding WFS1 protein, a transmembrane protein in the ER 
[67, 68]. However, the precise molecular mechanisms underlying β-cell death caused by 
the WFS1 mutation remain unknown. 
Our lab recently found that WFS1 is a component of the UPR, and that it 
functions in mitigating ER stress in pancreatic β-cells [69]. We also found that WFS1 
mRNA and protein are induced by ER stress and that expression of WFS1 is regulated by 
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IRE1 and PERK. WFS1 is normally upregulated during insulin secretion, whereas the 
inactivation of WFS1 in β-cells causes a high level of ER stress and, consequently, β-cell 
dysfunction. The suppression of WFS1 causes an imbalance in ER homeostasis and leads 
to an increase in the expression of the ER stress markers BiP, CHOP, Ero1α, spliced 
XBP-1, and total XBP-1 in INS-1 832/13 cells, a rat pancreatic β-cell line. Our lab has 
recently found that WFS1 negatively regulates the function of XBP-1 and ATF6 
(Fonseca, S. and Urano, F., unpublished data). This finding indicates that WFS1 has an 
important function in mitigating high levels of ER stress and maintaining ER homeostasis 
in pancreatic β-cells, suggesting that β-cell death in Wolfram syndrome is caused by 
chronic and high levels of ER stress. WFS1 knockout mice also develop diabetes due to 
β-cell apoptosis induced by ER stress [70]. These results indicate that the pathogenesis of 
Wolfram syndrome involves chronic ER stress in pancreatic β-cells caused by the loss of 
function of WFS1. 
In addition to these rare genetic forms of Type 1 diabetes, emerging evidence 
suggests that all three upstream signaling components of ER stress, PERK, ATF6, and 
IRE1, may play important roles in the progression to type 2 diabetes mediated by ER 
stress. Regulation of translation initiation through PERK/eIF2α is necessary for ER stress 
signaling to prevent β-cell dysfunction when the demand for insulin is increased due to 
high fat diet and insulin resistance [58]. These studies also show that β-cells have a 
unique requirement for PERK regulated translation, and suggest that β-cell dysfunction 
and death can be caused by a high level of ER stress. More recently, it was shown that 
common variants in the ATF6 gene are associated with elevated glucose levels in the 
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general population, and are significantly associated with type 2 diabetes and disturbed 
glucose homeostasis [71]. However, the physiological functions of ATF6 in pancreatic β-
cells are not yet known.  
It has been shown that in the presence of chronic ER stress, IRE1 activates JNK 
through ASK1 and elicits apoptosis in neurons [72] . This pathway may block the 
functions of the anti-apoptotic BCL2 family members Bcl2 and Bcl-XL by 
phosphorylating them, thus causing apoptosis in β-cells. It also is possible that this 
pathway enhances the functions of two proapoptotic factors, Bax and Bak, and causes 
apoptosis [73]. Additionally, it recently has been suggested that activation of IRE1-JNK 
signaling is an important contributor to insulin resistance in the liver cells of patients with 
Type 2 diabetes. Obesity causes ER stress in the liver and leads to hyperactivation of 
IRE1-JNK signaling [74]. This, in turn, causes serine phosphorylation of insulin receptor 
substrate-1 (IRS-1) and inhibits insulin action in liver cells. Therefore, a high level of ER 
stress in liver cells contributes to the development of insulin resistance in Type 2 
diabetes. Although it is not clear what causes ER stress in the liver, one possibility is that 
the baseline level of ER stress is high in hepatocytes, as it is in pancreatic β-cells, and 
that those cells are susceptible to additional ER stress. Taken together, these studies 
implicate high levels of ER stress in the progression to diabetes. 
The major characteristic of Type 2 diabetes is peripheral resistance to the action 
of insulin; this resistance leads to a compensatory prolonged increase in insulin 
biosynthesis and secretion. However, hyperglycemia and Type 2 diabetes only develops 
in subjects that are unable to sustain the β-cell compensatory response [75]. The failure of 
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β-cells to compensate for the increased demand for insulin caused by insulin resistance is 
progressive, particularly occurring after the onset of hyperglycemia. This leads to 
deterioration in β-cell function and eventual loss of β-cell mass from apoptosis [76]. 
During the β-cell’s compensatory attempt to increase insulin production, the folding 
capacity of the β-cell ER is overwhelmed. Thus, peripheral resistance to insulin activates 
ER stress-signaling pathways. Studies have shown that compensation fails in subjects that 
have “susceptible” as opposed to “robust” β-cells [77]. β-cell susceptibility is not well 
understood but is determined by a combination of genetic and environmental factors. For 
this reason, chronic ER stress in β-cells may lead to β-cell death in patients with Type 2 
diabetes who are genetically susceptible to ER stress or have a defect in ER stress 
signaling (i.e. UPR).  
When we began this work, some genetic evidence existed that implicated ER 
stress and defective ER stress signaling in the development of rare forms of experimental 
and clinical diabetes. This evidence suggested that the insulin-secreting β-cell may be 
especially sensitive to the adverse effects of perturbed ER function. Compared to other 
differentiated cells, the β-cell requires periodic increases in its capacity to fold and 
secrete insulin in response to increases in blood glucose. Mutations or deletions of the ER 
stress transducer PERK had been implicated in β-cell dysfunction due to the inability to 
downregulate protein biosynthesis in response to increased insulin production. These 
studies implied both a physiological and pathological role for ER stress signaling in 
pancreatic β-cells. Preliminary work had shown that both PERK, and the functionally 
similar IRE1, were upregulated in pancreatic β-cells under normal conditions, however 
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the role of IRE1 in these cells had not been studied extensively.  Because PERK signaling 
had been proposed to play an important role in β-cell homeostasis and insulin 
biosynthesis, we wanted to further investigate the role of IRE1 in these processes.  
Additionally, the revelation that the IRE1-XBP-1 signaling pathway was critical 
for the differentiation of plasma cells lead to the hypothesis that ER stress signaling may 
play an essential physiological role in the function of many different types of professional 
secretory cells. Thus we asked the question, what are the physiological and pathological 
roles of ER stress signaling in pancreatic β-cells?  This information could give insight 
into the normal function of pancreatic β-cells and also shed light onto unknown processes 
involved in insulin biosynthesis and β-cell homeostasis. Here we show that ER resident 
protein kinase IRE1 plays an essential role in the positive regulation of insulin 
biosynthesis and that physiological ER stress has a beneficial effect in pancreatic β-cells. 
However, we also show that prolonged activation of IRE1 signaling negatively affects β-
cells in that it results in a decrease in insulin gene expression. Thus, our work implicates 
chronic ER stress in the mechanisms of glucose toxicity.  Lastly, we provide evidence 
that the IRE1-mediated decrease in insulin mRNA may be part of a protective mechanism 








PHYSIOLOGICAL ER STRESS HAS A BENEFICIAL EFFECT IN 
PANCREATIC β-CELLS AND PLAYS A ROLE IN THE  
REGULATION OF INSULIN BIOSYNTHESIS  
Summary 
In pancreatic β-cells, the endoplasmic reticulum (ER) is an important site for 
insulin biosynthesis and the folding of newly synthesized proinsulin. Thus, β-cells have 
an elaborate ER that functions to maintain ER homeostasis.  An imbalance in ER 
homeostasis caused by high physiological load or pathological conditions elicits ER 
stress. The unfolded protein response (UPR) is an intracellular adaptive response to ER 
stress.  Inositol Requiring 1α (IRE1α), an ER-resident transmembrane protein kinase, is 
an upstream component of the UPR and a central regulator of ER stress signaling. Here 
we show that IRE1α has a crucial function in insulin biosynthesis. IRE1α 
phosphorylation is coupled to insulin biosynthesis in response to transient exposure to 
high glucose; inactivation of IRE1α signaling by siRNA or inhibition of IRE1α 
phosphorylation using a dominant negative kinase inactive mutant hinders insulin 
biosynthesis. IRE1α activation by acute exposure to high glucose does not accompany 
XBP-1 splicing or BiP dissociation but does upregulate a subset of UPR target genes such 
as ERO1α and WFS1. Thus, IRE1 signaling activated by transient exposure to high 
glucose utilizes a unique subset of downstream components and has a beneficial effect in 
pancreatic β-cells.  In contrast, chronic exposure of β-cells to high glucose causes ER 
stress and hyperactivation of IRE1, leading to the suppression of insulin gene expression. 
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Introduction 
Pancreatic β-cells are specialized for the production and regulated secretion of 
insulin to control blood glucose levels. In the presence of hyperglycemia, pancreatic β- 
cells secrete insulin from a readily available pool. At the same time, an increase in insulin 
release activates insulin biosynthesis. The endoplasmic reticulum (ER) plays an 
important role in the biosynthesis of insulin. The frequent fluctuation of blood glucose 
levels in humans requires that β-cells control proinsulin folding in the ER with exquisite 
sensitivity. Any imbalance between the physiological load of insulin translation into the 
ER and the capacity of the ER to properly fold and process the insulin negatively affects 
the homeostasis of β-cells and leads to ER stress [17, 78].  
The unfolded protein response (UPR) is an intracellular system that mitigates ER 
stress. It has been demonstrated that Inositol Requiring 1 (IRE1), an ER-resident 
transmembrane protein kinase, is an upstream component of the UPR and a central 
regulator of UPR-specific downstream gene expression. IRE1 senses the presence of 
unfolded and misfolded proteins in the ER, which causes dimerization, trans-
autophosphorylation and subsequent activation of IRE1. Activated IRE1 then splices X-
box binding protein-1 (XBP-1) mRNA, which leads to synthesis of the active 
transcription factor XBP-1 and upregulation of UPR genes. These include ER-associated 
protein degradation genes and genes important for protein folding [47, 79, 80] IRE1-
XBP-1 signaling is also important for expansion of the ER, which in turn, is required for 
the differentiation of secretory cells [51, 52, 81]. If the overload of unfolded proteins in 
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the ER is not resolved via the UPR, prolonged activation of IRE1 causes activation of 
JNK kinases, which can lead to apoptosis[53, 72]. 
Mammalian cells have two isoforms of IRE1, α and β. IRE1α is expressed 
ubiquitously, with high levels of expression in the pancreas and placenta [82] while 
IRE1β is expressed only in epithelial cells of the gastrointestinal tract [83, 84]. It has 
been shown that IRE1-XBP-1 signaling is particularly important in cells that are active in 
protein secretion, such as antibody-secreting plasma cells, hepatocytes, and exocrine 
pancreatic cells [47, 51, 52, 81, 85]. Studies in these cells suggested that physiological 
ER stress may be necessary for proper differentiation and function in secretory cells. 
However, the IRE1-XBP-1 signaling pathway in endocrine cells, (i.e., pancreatic β-cells) 
had not been studied extensively, and few physiological inducers of ER stress had been 
identified. Also, no previous studies had reported that activation of IRE1 signaling 
pathways had a function in regulated synthesis of secretory proteins. 
Most previous studies of ER stress signaling were done with the use of severe ER 
stress inducing drugs which simultaneously and strongly activate all subpathways of the 
UPR. While these approaches were critical to the overall understanding of UPR signaling 
function, we now wanted to further investigate the role of ER stress signaling under more 
physiologically relevant conditions. What were the roles of ER stress signaling in normal 
cellular function? Based on the studies showing a unique requirement of plasma cells for 
IRE1 signaling, we hypothesized that under various physiologically relevant stress 
conditions, each individual UPR subpathway might provide a unique and specialized 
role. The β-cell requires periodic increases in its capacity to fold and secrete insulin in 
 20 
response to acute increases in blood glucose. Thus, we undertook this study to test the 
idea that acute exposure of pancreatic β-cells to high glucose levels causes physiological 
amounts of ER stress and activates IRE1α signaling. What follows is our characterization 
of the IRE1α signaling subpathway and its effects on insulin biosynthesis in pancreatic β-
cells. Here we show that acute exposure to high glucose activates IRE1α and a unique 
subset of downstream components of IRE1α. Under these conditions, IRE1α activation 
has a beneficial effect, aiding in the enhancement of postprandial proinsulin biosynthesis 
in pancreatic β-cells. However, we also show that chronic exposure of β-cells to high 
glucose conditions hyperactivates IRE1α, and correlates with a suppression of insulin 
gene expression.  Our results imply both a physiological and pathological role for ER 













Materials and Methods 
 
Cell Culture and Transfection of Small Interfering RNA 
Rat insulinoma cells, INS-1 and INS-1 832/13, and mouse islets were cultured in 
RPMI 1640 supplemented with 10% FBS. The Cell Line Nucleofector Kit T with the 
Nucleofector Device (Amaxa Biosystems, Gaithersburg, MD) was used to transfect small 
interfering RNA (siRNA) for IRE1α into INS1 cells. At QIAGEN (Valencia, CA), 
siRNAs for rat IRE1α were designed and synthesized: for rat IRE1α, 
AAGGCGATGATCTCAGACTTT. 
 
Glucose-Stimulated Insulin Secretion 
INS-1 832/13 cells were transfected with siRNA for IRE1α (final concentration: 
20 nM) and preincubated with 5 mM glucose overnight, then stimulated with 5 mM or 10 
mM glucose for 1 hour. We measured the insulin secretion level and cellular insulin 
content by radioimmunoassay (RIA) (Linco Diagnostics, St. Charles, MO) and calculated  
the ratio between secreted insulin and cellular insulin content. 
 
ELISA 
The ELISA assays were performed for mouse and rat insulin using the 1-2-3 




Immunoblotting and Immunoprecipitation 
Cells were lysed in ice-cold M-PER buffer (PIERCE, Rockford, IL) containing 
protease inhibitors for 15 minutes on ice then the lysates were cleared by centrifuging the 
cells at 13,000 x g for 15 min at 4°C. Lysates were normalized for total protein (10 mg 
per lane), separated using 4%–20% linear gradient SDS-PAGE (Bio Rad, Hercules, CA) 
and electroblotted. Anti-phospho IRE1α antibody was generated from bulk antiserum by 
affinity purification followed by adsorption against the nonphospho analog column 
peptide (Open Biosystems, Huntsville, AL). The peptide sequence for generating the 
antibody was CVGRH (pS) FSRRSG. This phosphopeptide was synthesized, multi-link-
conjugated to KLH, and used to immunize 2SPF rabbits. Rabbit anti-total-IRE1α 
antibody (B9134) was generated using a peptide, EGWIAPEMLSEDCK. Anti-actin 
antibody was purchased from Sigma (St. Louis, MO), anti-BiP (GRP78) and anti-PDI 
antibodies were purchased from Stressgen (Ann Arbor, MI), anti-eIF2α antibody was 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA), anti-phospho-eIF2α and 
anti-phospho-JNK antibodies were purchased from Cell Signaling (Danvers, MA), and 
anti-insulin antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) 
and Sigma (St. Louis, MO). For the immunoprecipitation, cells were lysed in ice-cold 
buffer (20 mM Hepes [pH 7.5], 1% Triton X-100, 150 mM NaCl, 10% glycerol, 1 mM 
EDTA) containing protease inhibitors for 15 minutes on ice. IRE1α was 





IRE1α wild-type and knockout fibroblasts were treated with 10 mM dithiothreitol 
(DTT) for 30 minutes. DTT was then washed out and chased with DMEM media for 0, 5, 
or 15 minutes. Cells were lysed in ice-cold M-PER buffer (PIERCE, Rockford, IL) 
containing protease inhibitors for 15 minutes on ice then the lysates were cleared by 
centrifuging the cells at 13,000 x g for 15 min at 4°C. Lysates were normalized for total 
protein (10 mg per lane), treated with 100 mM iodoacetamide, and separated using 4%–
20% linear gradient SDS-PAGE (Bio Rad, Hercules, CA) and electroblotted. PDI and 
actin were measured by immunoblot. 
 
Insulin Biosynthesis 
INS-1 cells were pretreated with 5 mM glucose in RPMI for 18 hr, then with 2.5 
mM glucose in KRB buffer (135 mM NaCl, 3.6 mM KCl, 10 mM Hepes [pH 7.4], 5 mM 
NaHCO3, 0.5 mM NaH3PO4, 0.5 mM MgCl2, 1.5 mM CaCl2) for 1 hour. The cells were 
stimulated with KRB buffer containing 16.7 mM of glucose for 1 hour. Lysates from 
those cells were subjected to SDS-PAGE. The active form of IRE1α (i.e., P-Ire1α) was 
detected by immunoblot analysis with anti-phospho specific IRE1α antibody and cellular 
expression levels of total IRE1α, insulin, and actin were measured by immunoblot 
analysis using the same lysates. We also measured the insulin secretion level and cellular 
insulin content by ELISA or RIA. Proinsulin biosynthesis was analyzed by proinsulin 
immunoprecipitation of [35S] methionine-radiolabeled INS-1 lysates as described [86-88]. 
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Immunoprecipitated 35S-labeled proinsulin was then subjected to SDS-PAGE and 
visualized by phosphorimaging. 
 
Islet Isolation from Mouse Pancreata 
Mice were anesthetized by intraperitoneal injection of sodium pentobarbital. 
Pancreatic islets were then isolated by pancreatic duct injection of 500 U/ml of 
collagenase solution followed by digestion at 37°C for 40 minutes with mild shaking. 
Islets were washed several times with HBSS, separated from acinar cells on a 
discontinuous Ficoll 400 gradient, viewed under a dissecting microscope, and hand-
selected. 
 
Real-Time Polymerase Chain Reaction 
Total RNA was isolated from the cells by the guanidine-thiocyanate-acid phenol 
extraction method and reverse transcribed using 1 mg of total RNA from cells with 
Oligo-dT primer. For the thermal cycle reaction, the ABI prism 7000 sequencer detection 
system (Applied Biosystems, Foster City, CA) was used at 50°C for 2 minutes, 95°C for 
10 minutes, then 40 cycles at 95°C for 15 seconds, and at 60°C for 1 minute.  
 The relative amount for each transcript was calculated by a standard curve of 
cycle thresholds for serial dilutions of cDNA sample and normalized to the amount of rat 
actin. The polymerase chain reaction (PCR) was performed in triplicate for each sample, 
then all experiments were repeated twice. The following sets of primers and Cyber Green 
(Applied Biosystems) were used for real-time PCR: for mouse actin, 
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GCAAGTGCTTCTAGGCGGAC and AAGAAAGGGTGTAAAACGCAGC; for mouse 
BiP, TTCAGCCAATTATCAGCAAACTCT and TTTTCTGATGTATCCTCTT 
CACCAGT; for mouse WFS1, CCATCAACATGCTCCCGTTC and 
GGGTAGGCCTCGCCATACA; for mouse Ero1α, GCTCTCTCCAAAGTGCTTCCA 
and TGCATCCTGAACTTTATTCCCA; for mouse Chop, 
CCACCACACCTGAAAGCAGAA and AGGTGAAAGGCAGGGACTCA; for mouse 
total XBP-1, TGGCCGGGTCTGCTGAGTCCG and 
GTCCATGGGAAGATGTTCTGG; for mouse spliced XBP-1, 
CTGAGTCCGAATCAGGTGCAG (original CAG sequence was mutated to AAT to 




Direct assay of IRE1 activation: generation of a phospho specific IRE1α antibody 
Previously, studies of IRE1 activation were assayed indirectly by measuring the 
splicing of one of its downstream targets, XBP-1. However, the degree to which IRE1 is 
phosphorylated is a direct measure of the IRE1 activation level. Accordingly, we 
measured the IRE1 activation level in endocrine pancreatic cells by generating an anti-
phospho-specific IRE1α antibody. We tested the specificity of that antibody by 
immunoblot analysis of wild-type and kinase inactive K599A human IRE1α [82] 
expressed in COS-7 cells. The antibody specifically detected wild-type IRE1α, which is 
autophosphorylated upon overexpression, but did not recognize the kinase-inactive 
mutant K599A (Figure 2.1A, upper panel). The expression of wild-type and kinase 
inactive K599A IRE1α was confirmed using an antibody that can recognize both 
phosphorylated and unphosphorylated IRE1α (total IRE1α) [89] (Figure 2.1A, lower 
panel). As previously reported, the expression level of kinase-inactive IRE1α was much 
higher than that of wild-type IRE1α  [82, 89]. 
IRE1α is activated by high glucose in pancreatic islets 
 Using anti-phospho-specific IRE1α antibody, we measured IRE1α activation 
levels in mouse pancreatic islets, whose primary function in the metabolism of glucose is 
to secrete insulin and glucagon. Therefore, we studied the effect of glucose on IRE1α 
activation by treating islets with two different concentrations of glucose, 2.5 mM and 
16.7 mM. Treating islets with a high concentration of glucose (16.7 mM) for 1 hour 
increased the phosphorylation level of IRE1α compared to 2.5 mM (Figure 2.1B left  
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Figure 2.1. IRE1α is activated by high glucose in pancreatic islets 
A) PIRE1A1 antibody specifically detects the phosphorylated form of IRE1α 
protein. Immunoblot analysis of wild-type and kinase-inactive K599A (IRE1αKA) human IRE1α expressed 
in COS-7 cells using PIRE1A1 antibody (P-IRE1α) or total IRE1α antibody. PIRE1A1 antibody 
specifically detects wild-type IRE1α, which is autophosphorylated by overexpression. The amount of total 
IRE1α is shown in the lower panel. 
 
B) Immunoblot analysis of Phospho-Ire1α (P-Ire1α) using lysates from mouse islets treated with 2.5 mM 
and 16.7 mM glucose (left panel), or 5 mM and 10 mM glucose (right panel) for 1 hour. 
 
C) C57BL/6mice fasted for 14 hours and were then injected intraperitoneally with glucose (2 mg/g) or 
water. Cellular expression levels of P-Ire1α and actin were determined by immunoblot analysis using the 
lysates from the islets of these mice. Blood glucose levels, measured by glucometer after 30 min of 
injection were >350 mg/dL in mice injected with glucose and <150 mg/dL in control mice. Plasma insulin 
levels were measured by ELISA after 1 hour of injection. Shown is a typical result of an experiment 
repeated three times. 
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panel), suggesting that IRE1α is activated in pancreatic islets in the presence of 
hyperglycemia. Because physiological concentrations of glucose usually fluctuate 
between 4 mM and 10 mM, we also treated islets with 5 mM and 10 mM glucose for 1 
hour and measured IRE1α phosphorylation. Treatment with 10 mM glucose also 
increased IRE1 phosphorylation (Figure 2.1B, right panel), indicating that IRE1α is 
activated by high physiological concentrations of glucose. The phosphorylation level of 
IRE1α by 5 mM glucose was higher than that by 2.5 mM glucose, suggesting that IRE1α 
activation level is coupled to the glucose concentration. To further study the relationship 
between glucose concentrations and IRE1α activation, we monitored IRE1α activation 
levels in vivo. We measured the phosphorylation levels of IRE1α in islets 1 hour after the 
injection of glucose into C57BL/6 mice. The glucose injection increased plasma insulin 
levels as expected. In addition, we found that the glucose-stimulated IRE1α 
phosphorylation and the degree of phosphorylation correlated with the levels of plasma 
insulin (Figure 2.1C). These results indicate that high glucose treatment activates IRE1α 
in the pancreatic islets.  
 To confirm this increase in IRE1α activation by high glucose treatment, we 
measured mRNA expression levels of ER stress markers in mouse islets treated with 2.5 
mM or 16.7 mM glucose for 1 hour using real-time polymerase chain reaction (PCR). 
Treatment with 16.7 mM glucose caused an increase in the expression of BiP, Wfs1, 
Ero1α, Chop, and total Xbp-1 (Figure 2A), markers for ER stress. Wfs1 is a target gene 
of IRE1 signaling in pancreatic β-cells [69]. Therefore, we expected that Xbp-1 splicing 




Figure 2.2. IRE1 signaling activated by high-glucose treatment in pancreatic islets upregulates a 
subset of ER stress response genes 
A) Mouse islets were pretreated with 2.5 mM glucose for 1 hour, then treated with 2.5 mM or 16.7 mM 
glucose for 1 hour. Expression levels of the ER stress markers BiP, Wfs1, Ero1α, Chop, total Xbp-1, and 






was not activated by high glucose treatment (Figure 2.2, lowest panel, right side). To 
confirm this observation, we treated mouse islets with 2.5 mM and 16.7 mM glucose or 
tunicamycin, a chemical inducer of ER stress for 1 hour, then measured IRE1α 
phosphorylation by immunoblot. We also measured the expression levels of total Xbp-1 
mRNA and spliced Xbp-1 mRNA by real-time PCR. Both high glucose and tunicamycin 
treatments induced IRE1α phosphorylation and upregulation of total Xbp-1 mRNA 
(Figure 2.3, top and lower left panels). However, only tunicamycin treatment, and not 
high glucose treatment, induced Xbp-1 splicing (Figure 2.3 lower right panel). These 
results suggest that while acute high glucose treatment activates IRE1, this activation 
may result in signaling independent of the IRE1-XBP-1 signaling pathway. 
 We hypothesized that the activation of IRE1α caused by transient exposure to 
high glucose has beneficial effects on the function of the pancreatic islets. The majority 
of cells in pancreatic islets are insulin producing β-cells. Thus, the activation of IRE1 
induced by high glucose in the islets prompted us to study the involvement of IRE1 
signaling in insulin biosynthesis in a β-cell line. Through the manipulation of glucose 
concentration in the insulinoma cell line, INS-1, we found that the IRE1α 
phosphorylation level increased correspondingly to increases in glucose. Furthermore this 
increase in IRE1α phosphorylation also correlated with increased insulin secretion by the 
cells. Treatment of INS-1 cells with high glucose (10, 20, and 25 mM) for 3 hours 
induced both insulin secretion and IRE1α phosphorylation (Figure 2.4), suggesting that 














       
 
Figure 2.3. IRE1 is activated by both high glucose and ER stress inducing agents but activation by 
glucose does not accompany XBP-1 splicing 
 Mouse islets were pretreated with 2.5 mM glucose for 1 hour, then treated with 2.5 mM glucose, 16.7 mM 
glucose, or tunicamycin (2.5 mg/ml) and 2.5 mM glucose for 1 hour. Expression levels of phospho- Ire1α 
(P-Ire1α), total Ire1α, and actin were measured by immunoblot. Expression levels of total and spliced Xbp-








Figure 2.4. IRE1α activation in insulinoma cells corresponds to glucose concentration and insulin 
secretion  
 INS-1 cells were pretreated with 5 mM glucose for 18 hour, and then with 2.5 mM glucose for 1 hour. The 
cells were stimulated with KRB buffer containing 0, 2.5, 10, 20, and 25 mM glucose for 3 hours. Cellular 
expression levels of phospho-Ire1α (PIre1α), total Ire1α, and actin were measured by immunoblot. The 
insulin secretion level was measured by ELISA and adjusted to the total amount of protein in cells.  
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Inhibition of IRE1 signaling decreases insulin biosynthesis 
Because IRE1 signaling is important for protein folding in the ER, we 
hypothesized that IRE1α positively regulates insulin secretion at the biosynthesis level. 
To study the role of IRE1α in proinsulin biosynthesis directly, we inhibited the 
expression of IRE1α in INS-1 cells, using siRNA specific for IRE1α. This suppression of 
IRE1α expression decreased cellular insulin content, but did not affect the expression 
level of glucokinase (Gck), another important β-cell protein, suggesting that the effects of 
siRNA are unique to insulin (Figure 2.5A). We also examined the effect of a dominant 
negative IRE1α mutant, which lacks kinase activity. The expression of mutant IRE1α, in 
which the ATP binding domain site at lysine residue 599 is replaced with alanine, 
decreased both the phosphorylation level of endogenous IRE1α and the insulin content in 
INS-1 cells (Figure 2.5B).  
To determine whether IRE1α controls insulin biosynthesis at the translation and 
protein-folding level, we measured proinsulin biosynthesis in INS-1 cells transfected with 
siRNA for IRE1α by metabolic pulse-labeling. IRE1α suppression was confirmed by 
immunoblot with anti-IRE1α antibody (Figure 2.5C, second panel). This suppression of 
IRE1α dramatically decreased proinsulin biosynthesis, indicating that IRE1α functions in 
insulin biosynthesis at the translation and protein folding level (Figure 2.5C, top panel). 
However, IRE1α suppression did not affect the expression levels of the ER proteins, 
PERK and PDI, or expression of cytoplasmic protein Gck. 
To confirm that the suppression of IRE1α by siRNA does not suppress general 
protein translation, we measured total protein biosynthesis by pulse-labeling, and found  
 34 
Figure 2.5. Inhibition of IRE1 signaling by siRNA decreases insulin biosynthesis in β-cells 
A) INS-1 cells were transfected with siRNA specific for rat Ire1α (final concentration, 20 nM) or siRNA 
for GFP as a control. Insulin, total Ire1α, glucokinase (Gck), and actin expression levels were analyzed by 
immunoblot.  
 
B) INS-1 cells were transfected with the kinase-inactive form of IRE1α (IRE1αK599A) or pcDNA3-EGFP. 
After transfection, the cells were pretreated with 2.5 mM glucose for 18 hours, then with 0 mM glucose for 
1 hour. Cells were stimulated with KRB buffer containing 25 mM glucose for 3 hours. Expression levels of 
total Ire1α, phosphorylated Ire1α (P-Ire1α), insulin, and actin expression were measured by immunoblot. 
 
C) INS-1 cells were transfected with siRNA specific for rat Ire1α (final concentration, 20 nM) or siRNA 
scramble as a control. After transfection, the cells were pretreated with 11 mM glucose for 18 hours, then 
stimulated with 16.7 mM glucose and incubated with [35S] methionine for 1 hour. 35S-labeled proinsulin 
was immunoprecipitated and subjected to SDS-PAGE analysis and visualized with a phosphoimager. 35S-
labeled total protein was also analyzed by SDS-PAGE followed by visualization with a phosphoimager. 
Expression levels of total Ire1α, PERK, PDI, Gck, and actin were measured by immunoblot. 
 
D) INS-1 832/13 cells were transfected with siRNA specific for rat Ire1α or scramble siRNA (final 
concentration, 20 nM). After transfection, the cells were pretreated with 5 mM glucose for 18 hour, then 
stimulated with 5 mM glucose or 10 mM glucose for 1 hour. Secreted insulin and cellular insulin content 
were measured by RIA: the ratio between secreted and cellular insulin (glucose-stimulated insulin 
secretion, GSIS) was calculated for each sample. 
C D 
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that total protein biosynthesis was not significantly affected by IRE1α siRNA (Figure 
2.5C, bottom panel). These results indicate that IRE1α signaling has a beneficial effect on 
pancreatic β-cells, enhancing insulin biosynthesis. To determine the effect of IRE1α on 
glucose-stimulated insulin secretion (GSIS: the ratio between secreted insulin and cellular 
insulin content), we measured GSIS in IRE1α-knockdown β-cells. We transfected INS-1 
832/13 cells with siRNA for IRE1α and preincubated the cells with 5 mM glucose 
overnight, then, stimulated the cells with 5 mM or 10 mM glucose for 1 hour and 
measured GSIS by radioimmunoassay (RIA). GSIS was not suppressed in IRE1α-
knockdown β-cells as compared to control cells with 5 mM glucose (Figure 2.5D, upper 
panel). GSIS was slightly decreased in IRE1α-knockdown β-cells with 10 mM glucose. 
These results suggest that IRE1α has an important function in proinsulin biosynthesis, but 
may not directly affect insulin secretion. Additionally, siRNA knockdown of IRE1α had 
no effect on insulin gene expression measured by real-time PCR (results not shown), 
suggesting the beneficial effect of IRE1α activation on insulin production occurs at the 
translation and protein folding level. 
High glucose induced phosphorylation of IRE1α requires glucose metabolism 
We next wanted to investigate further the mechanism by which IRE1α is activated 
in β-cells. To delineate the pathway by which IRE1α is activated by a high level of 
glucose, we studied the effects of a glucose analog, 2-deoxyglucose (2DG), on IRE1α 
activation by glucose. By treating INS-1 cells with 5 mM, 10 mM glucose, or 5 mM 
glucose with 10 mM 2DG, then measuring IRE1α phosphorylation levels, we found that  
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Figure 2.6 IRE1α activation by high glucose requires glucose metabolism 
 INS-1 cells were pretreated with 5 mM glucose overnight, then stimulated with 5 mM glucose, 10 mM 
glucose, 5 mM glucose with 10 mM 2-deoxyglucose (2DG), GLP-1 (20 nM) and 5 mM glucose, or a 
combination of GLP-1 and 5 mM glucose with 10 mM 2DG for 1 hr. Expression levels of phospho-Ire1α 






treatment with 2DG decreased IRE1α phosphorylation (Figure 2.6), indicating that 
glucose metabolism is, in fact, required for IRE1 activation. We also stimulated INS-1 
cells with a strong activator for insulin biosynthesis, using GLP-1 and 5 mM glucose as 
well as a combination of GLP-1 and 5 mM glucose with 2DG. Treatment with GLP-1 and 
5 mM glucose increased IRE1α phosphorylation, whereas treatment with a combination 
of GLP-1 and 5 mM glucose with 2DG prevented the GLP-1 induced increase in IRE1α 
phosphorylation (Figure 2.6). Because the activation of insulin biosynthesis by GLP-1 
requires glucose metabolism, this result supports our finding that glucose metabolism has 
an important function in IRE1α phosphorylation. 
IRE1α activation by insulin secretagogues differs from activation by chemical ER 
stress inducers 
The results from the 2DG treatment studies indicated that IRE1α activation by 
high glucose required the cells to metabolize the glucose. To test the extent to which 
IRE1α is activated by other stimuli, we treated INS-1 cells with a variety of known 
insulin secretagogues, including high glucose, arginine, tolbutamide, KCl, and GLP-1. 
We saw that all of these agents activated IRE1α phosphorylation (Figure 2.7A). Next, we 
wanted to compare the difference between IRE1 signaling activated by insulin 
secretagogues and to that activated by typical ER stress inducers. We treated INS-1 cells 
with two experimental ER stress inducers, tunicamycin and thapsigargin, and two insulin 
secretagogues, high glucose and GLP-1. Then, by immunoblot, we measured IRE1α 
phosphorylation, as well as IRE1’s two known downstream effector functions; XBP-1  
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Figure 2.7. The mechanism of IRE1α activation by insulin secretagogues is different from that of 
activation by chemical ER stress inducers 
A) INS-1 cells were pretreated with 5 mM glucose for 18 hours, then stimulated with glucose (5 mM and 
10 mM), arginine (10 mM), tolbutamide (25 mM), KCl (30 mM), or GLP-1 (20 nM) for 1 hour. Expression 
levels of phospho-Ire1α (P-Ire1α), total Ire1α, phospho-eIF2α (P-eIF2α), total eIF2α, and actin were 
measured by immunoblot.  
 
B) INS-1 cells were pretreated with 5 mM glucose for 18 hours, then stimulated with high glucose (16.7 
mM), tunicamycin (2.5 mg/ml), thapsigargin (1 mM), or GLP-1 (20 mM) for 3 hours. Expression levels of 
phospho-Ire1α (P-Ire1α), total Ire1α, Xbp-1, phospho-Jnk (P-Jnk), Perk, and actin were measured by 
immunoblot. 
 
C) INS-1 cells were pretreated with 5 mM glucose for 18 hours, then stimulated with 5 mM glucose, 16.7 
mM glucose, or tunicamycin (2.5 mg/ml) and 5 mM glucose for 3 hours. Ire1α was immunoprecipitated 
(IP) using lysates from the cells. IP products were immunoblotted (IB) with anti-BiP antibody. 
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splicing, and JNK phosphorylation. We also measured PERK expression levels. We 
found that GLP-1 and high glucose were the strongest activators of IRE1α (Figure 2.7B). 
However, we also observed that tunicamycin was the strongest activator of XBP-1 
splicing and thapsigargin was the strongest activator of JNK phosphorylation (Figure 
2.7B). These results show that insulin secretagogues activate IRE1α, but do not strongly 
activate known downstream components of IRE1 signaling, XBP-1 and JNK. This 
finding raised the possibility that IRE1α activation by high glucose (a physiological 
condition) and by tunicamycin and thapsigargin (experimentally induced, pathological 
conditions) occur by different mechanisms.  
It has been shown previously that IRE1 activation is controlled by an ER-resident 
molecular chaperone, BiP [25]. Under normal, unstressed conditions, BiP binds to the 
luminal domain of IRE1 and prevents its dimerization and activation. The accumulation 
of unfolded proteins in the ER (i.e., ER stress) correlates with the engagement of BiP 
with unfolded proteins and the subsequent release from IRE1, leading to IRE1 
dimerization and activation. To study how IRE1α is activated by different stimuli, we 
treated INS-1 cells with high glucose or tunicamycin, then examined the interaction 
between IRE1α and BiP by immunoprecipitation. As was reported, we found that BiP 
dissociated from IRE1α in response to tunicamycin treatment of INS-1 cells (Figure 
2.7C). However, BiP remained associated with IRE1α when INS-1 cells were treated 
with high glucose (Figure 2.7C), showing that IRE1α activation by a high level of 
glucose differs from its activation by tunicamycin treatment. Specifically, activation by 
high glucose does not require BiP dissociation. 
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Transient high glucose treatment causes IRE1 activation and upregulates a unique 
subset of downstream components of IRE1. 
 We had observed that acute treatment of β-cells with high glucose caused ER 
stress and resulted in IRE1α phosphorylation. However, activation of IRE1 with this 
stimulus did not result in activation of either known downstream signaling target of 
IRE1α; XBP-1 splicing or JNK phosphorylation. We also observed that this activation of 
IRE1α had a beneficial effect on proinsulin biosynthesis. We therefore wanted to further 
investigate how activation of IRE1α exerts its positive effects on insulin folding in the 
ER. We had shown that ERO1α, an ER-resident oxidoreductase that plays a key role in 
proinsulin folding, is upregulated by transient high glucose (Figure 2.2.). To investigate if 
IRE1α was involved in ERO1α expression, we treated WT and IRE1α -/- fibroblasts with 
the ER stress inducer tunicamycin for increasing time periods (Figure 2.8A). ERO1α 
mRNA was upregulated with increasing exposure to tunicamycin in the wild-type cells. 
However, in the IRE1α -/- cells, ERO1α upregulation was significantly reduced, 
indicating a role for IRE1α in the upregulation of ERO1α under ER stress conditions.  
 ERO1α is an activator of protein disulfide isomerase (PDI), which has a critical 
role in catalyzing the formation of disulfide bonds during protein folding in the ER [90-
92]. Thus, we hypothesized that the inability of IRE1α -/- cells to upregulate ERO1α in 
response to ER stress may also impact PDI. We challenged WT and IRE1α -/- cells with 




Figure 2.8.  IRE1α -/- cells are defective in ERO1α upregulation and PDI re-oxidation when 
challenged with ER stress 
A) IRE1α wild-type and knockout fibroblasts were treated with 2.5ug/ml tunicamycin for 0,1,3,or 5 hours. 
Expression levels of ERO1α were measured by real-time PCR. 
 
B) IRE1α wild-type and knockout fibroblasts were treated with 10 mM DTT for 30 minutes. DTT was 
washed out and chased with regular media for 0, 5, or 15 minutes. Lysates were treated with 100 mM 

































































































minutes, and then removed the DTT and let the cells recover (Figure 2.8B). We found 
that the IRE1α -/- cells were defective in the re-oxidation of PDI after DTT removal. 
Thus, IRE1α might beneficially impact cells though upregulation of ERO1α, which may  
activate proinsulin biosynthesis by enhancing the formation of the three critical disulfide 
bonds found in biologically active mature insulin. Because we did not observe XBP-1 
splicing or JNK phosphorylation under conditions that activate IRE1α and upregulate 
ERO1α, we suggest that IRE1α activation by high glucose controls a unique subset of 
components of IRE1α signaling including ERO1α and PDI. 
Sustained IRE1 signaling correlates with decreased insulin gene expression 
 Treatment of β-cells with high physiological concentrations of glucose for 1 hour 
enhances proinsulin biosynthesis. In contrast it is known that, paradoxically, chronic 
hyperglycemia is harmful to this adaptive response. To determine whether chronic 
hyperglycemia causes the typical activation of IRE1α and ER stress we treated mouse 
islets for 24 hours with 5 mM, 11 mM, and 16.7 mM glucose, then measured XBP-1 
splicing. This exposure of islets to high concentrations of glucose (11 mM and 16.7 mM) 
did cause XBP-1 splicing, indicating that chronic hyperglycemia induces typical IRE1 
activation and ER stress (Figure 2.9A). 
 We next cultured β-cells with low (2.5 mM), intermediate (11 mM), and high (25 
mM) concentrations of glucose for 3 and 7 days, then measured IRE1 activation levels 
and cellular insulin content to test whether a high level of sustained IRE1 
activation(i.e.,ER stress) has a harmful effect on insulin biosynthesis.  
 43 
  
Figure 2.9. Sustained activation of IRE1 signaling decreases insulin gene expression 
A) Mouse islets were treated with 5 mM, 11 mM, and 16.7 mM glucose for 24 hours. Spliced XBP-1 
mRNA expression levels were measured by quantitative real-time PCR. Error bars represent the SD of 
duplicate determinations. 
 
B) INS-1 cells were treated with 2.5 mM, 11 mM, and 25 mM glucose for 3 days and 7 days. Expression 
levels of total Ire1α, phosphorylated Ire1α, insulin, phosphorylated jnk,(both isoforms)  and actin were 
measured by immunoblot.  
 
C) INS-1 cells were treated with 2.5 mM, 11 mM, and 25 mM glucose for 7 days. Insulin 1 (Ins1) and 
insulin 2 (Ins2) mRNA expression levels were measured by quantitative real-time PCR. Error bars 
represent the SD of triplicate determinations. 
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Sustained activation of IRE1α by prolonged high glucose treatment resulted in increased 
JNK phosphorylation, further suggesting that chronic hyperglycemia may activate typical 
IRE1α controlled ER stress signaling pathways. Treatment of the cells with 11 mM 
glucose increased both the phosphorylation level of IRE1α and the cellular insulin 
content as compared to the levels in cells treated with 2.5 mM glucose (Figure 2.9B). 
Treatment with 25 mM glucose further increased the phosphorylation level of IRE1α, but 
decreased the cellular insulin content (Figure 2.9B), suggesting that hyperactivation of 
IRE1α may decrease insulin biosynthesis. To try to determine why high glucose 
treatment corresponded to a decrease in cellular insulin content, we also measured the 
expression levels of rat insulin mRNA in INS-1 cells treated with different concentrations 
of glucose for 3 days by real-time PCR. The expression levels of insulin mRNA 
dramatically decreased in the cells treated with 25 mM glucose (Figure 2.9C), suggesting 
that sustained activation of IRE1α (i.e., chronic ER stress) may decrease insulin 
biosynthesis at the transcription level. However, these observations may also reflect that 










 It has been shown that upstream components of ER stress signaling, IRE1 and 
XBP-1, play important physiological roles in the development of antibody-secreting 
plasma cells, hepatocytes, and exocrine pancreatic cells [52, 85]. Here, we have shown 
that regulated activation of IRE1α under physiological settings has an important function 
in pancreatic β-cells, and add β-cells to the growing list of secretory cells that require 
components of ER stress signaling for normal day-to-day activity. Postprandial 
hyperglycemia activates IRE1α, leading to the enhancement of proinsulin biosynthesis. 
We have therefore determined that glucose is a physiological activator of the UPR in 
pancreatic β-cells. Since the activation of IRE1 by transient exposure to high glucose 
does not accompany XBP-1 splicing or JNK activation, we have named this unique 
biological phenomenon ‘‘Stimulus-Coupling Adaptation to ER Folding (SCAEF)”. The 
components of SCAEF probably have important functions in proinsulin biosynthesis in 
pancreatic β-cells. For example, the ER-resident oxidoreductase ERO1α, is upregulated 
by transient high glucose and functions in proinsulin folding. Since ERO1α is an 
activator for PDI, which has a crucial role in disulfide bond formation, ERO1α may 
activate insulin biosynthesis by enhancing disulfide bond formation of proinsulin in the 
ER. Future studies may benefit greatly from the use of activators and components of 
SCAEF. These may help reveal different and, perhaps yet unknown, UPR pathways that 
are not evident through the manipulation of cells with severe ER stress inducing drugs 
such as tunicamycin and thapsigargin.  
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The activation of IRE1α by transient exposure to high glucose positively regulates 
proinsulin biosynthesis. It has been shown that another upstream component of ER stress 
signaling, PKR-like ER kinase (PERK), is also important in proinsulin biosynthesis [57]. 
PERK is highly expressed in pancreatic islets [37, 93]. Activated PERK phosphorylates 
the α subunit of eukaryotic translation initiation factor 2 (eIF2α), leading to the 
attenuation of general protein translation. This reduces the ER workload and protects 
cells against apoptosis resulting from ER stress [36]. In islets from PERK knockout mice, 
insulin biosynthesis stimulated by high glucose is markedly increased as compared to that 
in control mice, indicating that PERK is needed to suppress insulin biosynthesis by high 
glucose in β-cells [57]. This observation, combined with our present results, suggests that 
IRE1α may be a positive regulator and that PERK may be a negative regulator of insulin 
biosynthesis. Mutations in the EIF2AK3 gene encoding PERK have been reported in 
Wolcott-Rallison syndrome, a rare form of juvenile diabetes [56]. PERK knockout mice 
also develop diabetes as a consequence of a high level of ER stress in the pancreas [57]. 
Thus, the balance between IRE1α and PERK signaling appears to be important in the 
maintenance of β-cell homeostasis. Indeed, an imbalance between these two pathways 
may cause β-cell death. PERK and IRE1α may work together to monitor and properly 
regulate the amount of insulin translation occurring inside the β-cell ER in response to 
fluctuating blood glucose levels. 
Our results also suggest that IRE1 activation by high glucose occurs by a different 
mechanism than activation by tunicamycin, an extreme ER stress inducer. One current 
model of IRE1 activation is a ‘‘Competitive Deprivation’’ model of BiP dissociation 
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[25]. According to this model, BiP binds to the luminal ER domain of IRE1 under normal 
conditions and prevents dimerization and subsequent activation of IRE1. Under ER stress 
conditions, BiP engages with unfolded proteins in the lumen and is released from IRE1, 
leading to IRE1 dimerization and activation. It is known that BiP dissociates from IRE1 
under ER stress conditions caused by nonphysiological experimental conditions. Thus, it 
is possible that under extreme ER stress, BiP needs to be dissociated from IRE1 to fully 
activate IRE1 signaling, or to signal that conditions in the ER cannot be resolved via the 
UPR. However, the competitive deprivation model may not account for the adaptation to 
physiological ER stress caused by frequent fluctuations in protein folding in the ER. 
Recently, it was shown that the BiP binding domain of IRE1 is not the principal 
determinant of IRE1 activation [45]. Additionally, another group showed that IRE1 can 
be directly activated by unfolded proteins in the ER, and that BiP binding and release is 
not a requirement for control of IRE1 activity [46]. They suggested that BiP binding to 
IRE1 may serve to dampen activation of downstream IRE1 signaling targets (i.e., XBP-1 
or JNK) under conditions of mild ER stress [46]. Our finding of IRE1 activation without 
BiP dissociation by high glucose supports this possibility. 
Physiological activation of IRE1 (i.e., SCAEF) is unlikely to activate apoptosis 
signaling pathways. This conclusion is supported by our finding that high-glucose 
activation of IRE1 does not activate JNK signaling pathways, which in certain cell types 
are proapoptotic components of the UPR. However, we were surprised to find that XBP-1 
also is not spliced by transient high-glucose treatment either, indicating that IRE1-XBP-1 
signaling is not essential for insulin folding in β-cells under certain physiological 
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conditions. These observations are supported by work from the Glimcher laboratory 
showing that XBP-1 knockout mice have a severe exocrine pancreatic phenotype, 
whereas islets from these same mice are indistinguishable from wild-type islets [85]. It is 
possible that in endocrine pancreatic tissue, IRE1α has other target mRNAs that are 
subject to its endonuclease activity. These mRNAs may compete with XBP-1 mRNA so 
that XBP-1 is not spliced under physiological conditions when glucose is high and the β-
cells need to process large quantities of proinsulin. The physiological relevance of this 
mechanism, however, remains to be determined and requires further investigation. 
We have shown that IRE1 has important physiological functions in pancreatic β- 
cells: it is activated in response to high glucose and positively regulates proinsulin 
biosynthesis. Nevertheless, IRE1 activation could have a pathological effect under 
chronic pathological conditions or in other tissues. The major abnormality in patients 
with Type 2 diabetes is peripheral resistance to the action of insulin, which leads to a 
prolonged increase in insulin biosynthesis in response to elevated glucose levels. The 
secretion capacity of the ER is then overwhelmed, causing prolonged activation of the 
IRE1 signaling pathway. This could lead to glucose toxicity associated with 
hyperglycemia and insulin resistance. Glucose toxicity is defined as nonphysiological and 
potentially irreversible β-cell damage caused by chronic exposure to supraphysiological 
glucose concentrations [94, 95]. Our observation regarding IRE1 hyperactivation and the 
suppression of insulin biosynthesis suggests that chronic ER stress is a cause for glucose 
toxicity. However, this observation may also reflect that the stress response cannot keep 
up with the damage that chronic hyperglycemia causes. More studies are needed to 
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determine the relationship between IRE1 hyperactivation (i.e., ER stress) and glucose 
toxicity. 
In addition, activation of IRE1-JNK signaling is an important contributor to 
insulin resistance in the liver cells of patients with Type 2 diabetes. Obesity causes ER 
stress in the liver and leads to hyperactivation of IRE1-JNK signaling [74] which, in turn, 
causes serine phosphorylation of insulin receptor substrate-1 (IRS-1) and inhibits insulin 
action in liver cells. Therefore, a high level of ER stress in liver cells could contribute to 
the development of insulin resistance in patients with Type 2 diabetes. It has also been 
shown that a strong IRE1-JNK activation by the accumulation of expanded 
polyglutamine repeats seen in Huntington disease induces neuronal cell death[96]. These 
findings indicate that activation of IRE1 by pathological conditions, such as obesity, 
polyglutamine accumulation, and chronic hyperglycemia, is harmful to cells.  
In this study, we observed that chronic exposure to high glucose hyperactivates 
IRE1 and activates JNK. This activation of IRE1-JNK signaling in β-cells corresponds to 
reduction in insulin gene expression and cellular insulin content. Our results further 
support the idea that a high level of ER stress plays a pathological role in β-cell 
dysfunction. In contrast, we also show that physiological IRE1 activation by transient 
high glucose levels in pancreatic β-cells has a beneficial effect. Therefore, a drug or 
system to induce a physiological level of IRE1 activation could be used to enhance 
insulin biosynthesis and secretion in patients with diabetes, and could lead to the 




PATHOLOGICAL ER STRESS NEGATIVELY AFFECTS THE  
HOMEOSTASIS OF PANCREATIC β-CELLS AND RESULTS IN THE 
REDUCTION OF INSULIN GENE EXPRESSION 
Summary 
The endoplasmic reticulum (ER) is a cellular compartment that functions in 
protein folding.  Dysregulation of ER homeostasis elicits ER stress and subsequently 
activates cell signaling pathways, collectively known as the unfolded protein response 
(UPR). IRE1α is a central component of the UPR.  In pancreatic β-cells, IRE1α also 
functions in the regulation of insulin biosynthesis.  
The term “glucose toxicity” refers to the harmful metabolic effects of chronic 
hyperglycemia. Glucose toxicity is an impairment of insulin production and secretion in 
response to hyperglycemia and the underlying mechanisms responsible remain to be 
determined. Accumulating evidence has implicated JNK signaling in oxidative stress 
mediated suppression of insulin gene expression (i.e., glucose toxicity) in pancreatic β-
cells. Here we show that IRE1α signals through the JNK pathway in response to ER 
stress. In β-cells, ER stress activates IRE1α and correlates with a reduction in nuclear 
PDX-1. Inhibition of the IRE1α-JNK signaling pathway partially restores PDX-1 protein 
to the nucleus of pancreatic β-cells. Activation of the IRE1-JNK pathway by chronic high 
glucose treatment leads to increased serine phosphorylation of PDX-1, suggesting a 
potential mechanism of PDX-1 cytoplasmic relocalization.   
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Additionally, we show that hyperactivation of IRE1α caused by chronic high 
glucose treatment or IRE1α overexpression leads to insulin mRNA degradation in 
pancreatic β-cells.  Inhibition of IRE1α signaling using its dominant negative form 
prevents insulin mRNA degradation in β-cells.  Islets from mice heterozygous for IRE1α 
retain expression of more insulin mRNA after chronic high glucose treatment than do 
their wild-type littermates.   
These results reveal a role of IRE1α in insulin mRNA expression under ER stress 
conditions caused by chronic high glucose.  The rapid degradation of insulin mRNA 
could provide immediate relief for the ER and free up the translocation machinery. The 
slower transcriptional downregulation through PDX-1 inactivation may further ease the 
stress of translocating insulin. Thus, this mechanism would preserve ER homeostasis and 
help ensure that the insulin already inside the ER can be properly folded and secreted.  
This adaptation may be crucial for the maintenance of β-cell homeostasis and may 
explain why the β-cells of type 2 diabetic patients with chronic hyperglycemia stop 
producing insulin without simply undergoing apoptosis.  This mechanism may also be 
involved in suppression of the autoimmune diabetes (Type 1 diabetes) by reducing the 








The endoplasmic reticulum (ER) is a cellular compartment for the biosynthesis 
and folding of newly synthesized secretory proteins such as insulin. This environment in 
the ER is sensitive and can be perturbed by both pathological processes (viral infections) 
and physiological processes (large biosynthetic load placed on the ER).  This perturbation 
in ER function causes disregulation of ER homeostasis, and leads to ER stress [17, 78]. 
Simply defined, ER stress is a disequilibrium between ER load and folding capacity.  
 Cells cope with ER stress by activating an ER stress signaling cascade called the 
unfolded protein response (UPR).  This activation results in the upregulation of gene 
expression for molecular chaperones, expands the size of the ER, decreases general 
protein translation to reduce the ER workload, and degrades abnormal proteins 
accumulated in the ER [20, 28]. As long as ER stress signaling via the UPR can keep ER 
stress levels under control, cells can perform their normal functions.  However, under 
certain pathological conditions, including obesity, β-cell exhaustion in type 2 diabetes, 
and the progression of neurodegeneration, a high level of chronic ER stress persists, 
leading to cell dysfunction and death [72, 74, 97, 98]. It has been suggested that chronic 
and high levels of ER stress have a function in β-cell dysfunction and glucose toxicity.  
In glucose toxicity, insulin secretion by β-cells is impaired in response to stimulation by 
glucose; the condition is characterized by a sharp decline in insulin gene expression [95, 
99].  Numerous studies have shown that impaired β-cell disfunction can be improved by 
treatment of the hyperglycemia [95, 99], suggesting that identifying the molecular 
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mechanisms involved in β-cell glucose toxicity may provide new therapeutic targets for 
diabetes. 
Inositol Requiring 1 (IRE1), an ER-resident transmembrane protein kinase, is an 
upstream component of the UPR and a central regulator of UPR-specific gene expression 
and apoptosis[47, 53, 89].  Unfolded proteins in the ER lumen are sensed by IRE1, which 
causes its dimerization, trans-autophosphorylation, and subsequent activation.  Activated 
IRE1 then splices X-box binding protein 1 (XBP-1) mRNA, leading to synthesis of an 
XBP-1 transcription factor that upregulates specific UPR genes.[47, 48]  
If the overload of unfolded proteins in the ER is not resolved, chronic activation 
of IRE1 leads to activation of the c-Jun N-terminal kinase/stress activated protein kinase 
(JNK/SAPK) pathway[53]. Chronic ER stress causes IRE1 to bind c-Jun inhibititory 
kinase and recruit the cytosolic adaptor TRAF2[53]. This results in formation of an IRE1-
TRAF2 complex which signals through apoptosis-signaling kinase 1(ASK1) leading to 
JNK activation. [53, 72, 100, 101] Importantly, IRE1 -/- cells are defective in JNK 
activation in response to ER stress[53]. 
Accumulating evidence has implicated JNK signaling in oxidative stress mediated 
suppression of insulin gene expression (i.e., glucose toxicity)[102]. Transcription of the 
insulin gene is initiated by the binding of pancreatic and duodenal homeobox factor-1 
(PDX-1) to the A elements in the insulin gene promoter [103]. The A elements all share 
the consensus sequence TAAT, a recognition motif for PDX-1’s homeodomain [103, 
104]. The decline in insulin gene expression associated with glucose toxicity is 
accompanied by reduced expression or DNA binding activity of PDX-1 [105-109]. 
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Glucose metabolism has been shown to stimulate PDX-1 activity at the insulin promoter  
via JNK activation [110]. However, JNK overexpression decreases PDX-1 binding to the 
insulin promoter, and this correlates with a suppression of both insulin gene expression 
and secretion. JNK activation by oxidative stress induces the nucleocytoplasmic 
translocation of PDX-1 thus preventing the DNA binding activity of PDX-1 [111]. 
Additionally, expression of a dominant negative JNK preserves PDX-1 DNA binding 
activity in the presence of oxidative stress [102].  
Recent studies have shown that ER stress results in suppression of insulin receptor 
(IR) signaling through hyperactivation of the IRE1-JNK pathway. This leads to JNK 
induced serine hyperphosphorylation of insulin receptor substrate-1 (IRS-1) [74].  We 
therefore hypothesized that ER stress mediated hyperactivation of the IRE1-JNK pathway 
may also have similar effects on the phosphorylation state of PDX-1. In this chapter we 
show evidence that hyperglycemia induced ER stress hyperactivates the IRE1-JNK 
pathway resulting in PDX-1 hyperphosphorylation on serine residues. These JNK 
induced modifications correlate with a reduction of PDX-1 in the nucleus of pancreatic β-
cells and may affect PDX-1’s ability to activate insulin gene transcription. Our work 
shows the IRE1α-JNK ER stress signaling pathway is involved in the molecular 
mechanisms in the reduction of PDX-1 from the nucleus of pancreatic β-cells, however 
this alone cannot account for the dramatic reduction in insulin mRNA observed during 
chronic exposure to high glucose levels. Thus our study continues by exploring another 
mechanism by which ER stress and IRE1α signaling may impact insulin gene expression. 
 55 
In metazoans, IRE1 activation initiates two separate signaling cascades: an XBP-
1-dependent pathway that upregulates ER stress response genes, and an XBP-1-
independent pathway involving specific cleavage and subsequent degradation of sets of 
translating mRNAs on the ER membrane [55]. This response complements other 
components of the UPR, selectively halting protein synthesis and clearing the 
translocation machinery when translating mRNAs are overloading the ER and causing 
ER stress.  It has been suggested that this specific mRNA degradation may result from 
IRE1 focusing on messages that present the most immediate challenge to the 
translocation and folding machinery[55]. 
In mice and rats, the two insulin gene transcripts are the most abundantly 
transcribed mRNAs in β-cells bound for translation through the ER membrane [112].   
Global profiling of genes modified by ER stress in β-cells has shown that upon induction 
of ER stress, insulin 1 and insulin 2 mRNA are quickly degraded, leading to significantly 
decreased levels of these mRNAs [113]. We have shown in Chapter II that 
hyperactivation of IRE1 is correlated with a reduction in insulin mRNA expression in 
pancreatic β-cells [98]. Based on these observations, we hypothesized that when ER 
folding capacity is overwhelmed, IRE1 initiates endonucleolytic cleavage of mRNA 
encoding insulin, the major secretory protein in pancreatic β-cells.  In this chapter, we 
suggest that prolonged activation of IRE1 observed upon chronic high glucose exposure 
may contribute to the reduction in insulin gene expression in two ways; IRE1α-mediated 
insulin mRNA degradation, and IRE1α-JNK-mediated PDX-1 inactivation.  These effects 
may act synergistically to decrease insulin mRNA. What follows is our characterization 
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of these two effects elicited by IRE1 signaling in pancreatic β-cells. Here we report that 
IRE1α hyperactivation has a function in insulin mRNA reduction under chronic high-
glucose conditions and implicate ER stress in the molecular mechanisms of glucose 




Materials and Methods 
 
Cell culture and transfection of small interfering RNA and plasmid DNA 
Rat insulinoma cells, INS-1 832/13 cells, were a gift from Dr. Christopher Newgard 
(Duke University Medical Center). INS-1 832/13, and mouse islets were cultured in 
RPMI 1640 supplemented with 10% FBS. COS7 cells were cultured in DMEM 
supplemented with 10% FBS and transfected using the FuGene Transfection Reagent 
(Roche, Basel, Switzerland). Cell Line NucleofectorTM Kit V with the Nucleofector 
Device (Amaxa Biosystems, Gaithersburg, MD) was used to transfect small interfering 
RNA (siRNA) for IRE1α into INS1 832/13 cells.  At QIAGEN (Valencia, CA) siRNAs 
for rat IRE1α were designed and synthesized: for rat IRE1α, 
AAGGCGATGATCTCAGACTTT. Nucleofection was also used to transfect INS1 
832/13 cells with pcDNA3.0 and DN-Traf2-Flag in pcDNA3.0. 
 
Separation of nuclear and cytoplasmic cell lysates and immunoblotting 
Lysates were extracted using NE-PER® Nuclear and Cytoplasmic Extraction Reagents 
(Pierce Biotechnology, Rockford, IL) supplemented with protease inhibitors. Lysates 
were normalized for total protein (20 µg per lane), separated using 4%-20% linear 
gradient SDS-PAGE (Bio Rad, Hercules, CA), and transferred to a nitrocellulose 
membrane. After blocking for 1h at room temperature in TBS-T with 5% nonfat dry milk, 
membranes were incubated at 4°C overnight in TBS-T with 5% nonfat dry milk 
containing a 1:1000 dilution of antibody and washed 3 times with TBS-T. The 
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membranes were then incubated for 1 h at room temperature in TBS-T with 5% nonfat 
dry milk containing a 1:3000 dilution of anti-rabbit IgG antibody (Bio Rad) coupled to 
horseradish peroxidase, followed by washing 3 times with TBS-T. Immunoreactive bands 
were visualized by incubation with Pierce ECL and exposed to x-ray film. For total 
protein lysate analysis, cells were lysed in ice-cold M-PER buffer (PIERCE, Rockford, 
IL) containing protease inhibitors for 15 min on ice.  The lysates were then cleared by 
centrifuging the cells at 13,000 x g for 15 min at 4°C.  Lysates were normalized for total 
protein (10 µg per lane), separated using 4%-20% linear gradient SDS-PAGE (Bio Rad, 
Hercules, CA), and electroblotted. Anti-phospho IRE1α antibody was generated from 
bulk antiserum by affinity purification followed by adsorption against the nonphospho 
analog column peptide [98]. Total IRE1α was measured with anti-total-IRE1α antibody 
NY200 [25]. Anti-actin antibody and Anti-Flag antibody were purchased from Sigma (St. 
Louis, MO). Anti-PDX-1 and anti-phospho-JNK antibodies were purchased from 
Upstate/Cell Signaling (Lake Placid, NY) XBP-1 antibody was purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA) 
 
Generation of IRE1α heterozygous mice 
Mice heterozygous for the Ire1α (Ire1α+/–) gene [53] were backcrossed with 129SvEv 




Real-time polymerase chain reaction 
Total RNA was isolated from the cells by using RNeasy Mini Kit (Qiagen), then reverse- 
transcribed using 1 µg of total RNA from cells with Oligo-dT primer. For the thermal 
cycle reaction, the iQ5 system (BioRad) was used at 95°C for 10 min, 40 cycles at 95°C 
for 10 sec, and at 55°C for 30 sec. The relative amount of each transcript was calculated 
by a standard curve of cycle thresholds for serial dilutions of cDNA sample and 
normalized to the amount of actin.  PCR was done in triplicate for each sample. The 
following sets of primers and Power SYBR Green PCR Master Mix (Applied 
Biosystems) were used for real-time PCR: for mouse actin, 
GCAAGTGCTTCTAGGCGGAC and AAGAAAGGGTGTAAAACGCAGC; for mouse 
insulin1, GAAGTGGAGGACCCACAAGTG and CTGAAGGTCCCCGGGGCT; for 
mouse insulin2, TGCTGATGCCCTGGCCTGCTCT and CTGGTCCCACATATG 
CACATGCA; for mouse CHOP, CCACCACACCTGAAAGCAGAA and 
AGGTGAAAGGCAGGGACTCA; for mouse total XBP-1, 
TGGCCGGGTCTGCTGAGTCCG and GTCCATGGGAAGATGTTCTGG; for mouse 
spliced XBP-1, CTGAGTCCGAATCAGGTGCAG (original CAG sequence was 
mutated to AAT to reduce the background signal from unspliced XBP-1) and 
GTCCATGGGAAGATGTTCTGG; for rat actin, GCAAATGCTTCTAGGCGGAC and 
AAGAAAGGGTGTAAAACGCAGC; for rat Glut2, 
GTGTGAGGATGAGCTGCCTAAA and TTCGAGTTAAGAGGGAGCGC; for rat 
insulin 1, GTCCTCTGGGAGCCCAAG and ACAGAGCCTCCACCAGG; for rat 
insulin 2, ATCCTCTGGGAGCCCCGC and AGAGAGCTTCCACCAAG; for rat spliced 
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XBP-1, CTGAGTCCGAATCAGGTGCAG (original CAG sequence was mutated to 




Cellular mRNA transcription was attenuated by treating cells with 100 µg/mL 
actinomycin D (Sigma A-4262) for 1 hr followed by treatment with 1µM thapsigargin for 
different time periods. Total RNA was isolated from the cells using the RNeasy Mini Kit 
(Qiagen). Reverse-transcribed RNA was subjected to real-time PCR quantitation to 
measure levels of insulin gene transcripts. The relative amount of each transcript was 
calculated by a standard curve of cycle thresholds for serial dilutions of cDNA sample 
and normalized to the amount of actin. Time point zero for each condition was 












Early inquiries into the effects of long term exposure to high glucose included a 
study that demonstrated that glucose can decrease insulin gene expression in INS-1 cells, 
a cell line able to secrete insulin in response to physiologic glucose concentrations [107]. 
Surprisingly, the researchers observed that the glucose-induced decrease in insulin gene 
expression occurred after only 48 hours of exposure to high glucose concentrations.  
However, they did observe the same diminished binding activity of PDX-1 to the insulin 
gene promoter seen in cell lines treated with glucose for weeks or months.  Their results 
suggest that similar molecular mechanisms may be at work in the glucose desensitization 
of the insulin gene in the INS-1 cell line. INS-1 cells are therefore an excellent in vitro 
model to study glucose toxicity and thus are our cells of choice in the following study. 
 
ER stress activates IRE1α and correlates with a reduction of PDX-1 from the 
nucleus of pancreatic β-cells 
 To study the role of ER stress in PDX-1 nuclear localization, we first treated INS-
1 832/13 cells for 3 hours with increasing concentrations of glucose, as well as 
physiological levels of glucose with experimental ER stress inducing drugs tunicamycin 
or thapsigargin (Figure 3.1A). Nuclear PDX-1 was lowest in 2.5 mM glucose treated 
cells, and increased correspondingly as glucose concentration increased. However, 
inducing ER stress by treatment with both tunicamycin and thapsigargin reduced nuclear 
PDX-1, with thapsigargin having the most dramatic effect. As we have previously 
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reported, tunicamycin was the strongest inducer of XBP-1 splicing, while thapsigargin 
was the strongest activator of JNK phosphorylation.  
To confirm that thapsigargin was activating ER stress signaling pathways, we 
treated INS-1 832/13 cells with low glucose, high glucose, or thapsigargin for 3 hours 
and measured IRE1α phosphorylation by immunoblot (Figure 3.1B). We observed IRE1α 
activation by both high glucose and thapsigargin, however, strong JNK phosphorylation 
was seen only by treatment with thapsigargin. Because chronic treatment of β-cells with 
high glucose correlates with very strong phosphorylation of IRE1α , and because JNK 
has been solidly implicated in reduction of PDX-1 from the nucleus, we next treated INS-
1 832/13 cells with low or high glucose for 3 days. We observed that treatment with 16.7 
mM glucose for 3 days strongly activated both IRE1α and JNK, and correlated with a 
reduction in nuclear PDX-1 (Figure 3.1C). We therefore hypothesized that activation of 
the IRE1α-JNK ER stress signaling pathway by chronic high glucose treatment is similar 
to the transient activation of this pathway in only 3 hours by the drug thapsigargin. That 
is, both chronic high glucose and transient treatment with thapsigargin cause strong 









Figure 3.1. ER stress activates IRE1α and correlates with a reduction of PDX-1 from the nucleus of 
pancreatic β-cells 
A) INS-1 832/13 cells were pretreated with 5 mM glucose for 20 hours, and then with 2.5 mM glucose for 
1 hour. The cells were then stimulated with KRB buffer containing 2.5 mM, 5 mM, or 16.7 mM glucose or 
5 mM glucose plus tunicamycin (2.5 µg/mL) or thapsigargin (1 µM) for 3 hours. Cytoplasmic and nuclear 
fractions were collected and cellular expression levels of cytoplasmic and nuclear PDX-1, spliced XBP-1, 
phosphorylated JNK and actin were measured by immunoblot. 
 
B) INS-1 832/13 cells were pretreated with 5 mM glucose for 20 hours, and then with 2.5 mM glucose for 
1 hour. The cells were then stimulated with KRB buffer containing 5 mM or 16.7 mM glucose or 5 mM 
glucose and thapsigargin (1 µM) for 3 hours. Cytoplasmic and nuclear fractions were collected and cellular 
expression levels of phosphorylated IRE1α, cytoplasmic and nuclear PDX-1, and actin were measured by 
immunoblot. 
 
C) INS-1 832/13 cells were incubated in 5 mM glucose RPMI or 16.7 mM glucose RPMI for 72 hours. 
Cytoplasmic and nuclear fractions were collected and expression levels of phospho-IRE1α, phospho-JNK, 





Inhibition of the IRE1α-JNK signaling pathway partially restores PDX-1 protein to 
the nucleus of pancreatic β-cells  
To test the involvement of the IRE1α-JNK signaling pathway in PDX-1 cellular 
localization directly, we inhibited the expression of IRE1α in INS-1 832/13 cells using 
siRNA specific for IRE1α (Figure 3.2A). After a 20 hour treatment with either IRE1α 
siRNA or control siRNA, we treated the cells with low glucose, high glucose, or 
thapsigargin for 3 hours and measured total IRE1α, JNK phosphorylation and PDX-1. 
The suppression of IRE1α expression decreased the amount of JNK phosphorylation and 
restored the amount of nuclear PDX-1 in the cells, as compared to treatment with control 
siRNA. 
It has been previously shown the IRE1α activates JNK through the cytosolic 
adapter protein TRAF2. To this end, we examined the dominant negative effect of a 
mutant TRAF2 protein on PDX-1 cellular localization (Figure 3.2B). After transfection 
with either DN-TRAF2 or pcDNA3.0 control plasmid, cells were treated with low 
glucose, high glucose, or thapsigargin for 3 hours and again total IRE1α, JNK 
phosphorylation and PDX-1were measured. The suppression of TRAF2 signaling both 
reduced JNK phosphorylation upon ER stress and partially preserved PDX-1 protein in 
the nucleus. Taken together, these results suggest that the IRE1α-JNK ER stress signaling 
pathway is involved in the molecular mechanisms in the reduction of PDX-1 from the 





























Figure 3.2. Inhibition of the IRE1α-JNK signaling pathway restores PDX-1 protein to the nucleus of 
pancreatic β-cells 
A) INS-1 832/13 cells were transfected with siRNA specific for rat IRE1α (final concentration 20 nM) or 
control siRNA and incubated in 5mM glucose. 20 hours post-transfection, cells were incubated in 2.5 mM 
glucose for 1 hour. The cells were then stimulated with KRB buffer containing 5 mM or 16.7 mM glucose 
or 5mM glucose and thapsigargin (1 µM) for 3 hours. Cytoplasmic and nuclear fractions were collected and 
cellular expression levels of total IRE1α, cytoplasmic and nuclear PDX-1, phospho-JNK, and actin were 
measured by immunoblot. 
 
B) INS-1 832/13 cells were transfected with either a dominant negative form of TRAF2 tagged with Flag or 
with pcDNA3.0 plasmid as a control and incubated in 5 mM glucose for 20 hours. Cells were then 
pretreated with 2.5 mM glucose for 1 hour and stimulated with KRB buffer containing  5 mM or 16.7 mM 
glucose or 5 mM glucose and thapsigargin (1 µM) for 3 hours. Cytoplasmic and nuclear fractions were 
collected and cellular expression levels of Flag, cytoplasmic and nuclear PDX-1, phospho-JNK, and actin 




Chronic high glucose causes intense activation of the IRE1-JNK pathway and strong 
serine phosphorylation of PDX-1 by JNK. 
Hyperactivation of the IRE1α-JNK signaling pathway in liver cells leads to 
increased serine phosphorylation of IRS-1 by JNK [74]. We questioned whether this 
could be an explanation for PDX-1 reduction from the nucleus upon ER stress in 
pancreatic β-cells. We treated INS-1 832/13 cells with low glucose, high glucose, or 
thapsigargin for 3 hours or treated INS-1 832/13 cells with 5 mM or 16.7 mM glucose for 
3 days followed by immunoprecipitation with anti-PDX-1 antibody (Figure 3.3 A and B). 
We then immunoblotted with antibody specific for phosphorylation on serine residues. 
We observed strong serine phosphorylation in the cells treated with 16.7 mM glucose for 
3 days. However, we did not observe this same phosphorylation of serine for the 3 hour 
thapsigargin treated cells. This result suggests that the effects on the phosphorylation of 
PDX-1 by chronic high glucose treatment cannot be mimicked with transient treatment 
with thapsigargin in only 3 hours. Although both chronic high glucose and transient 
thapsigargin treatment cause ER stress and activation of the IRE1α-JNK signaling 
pathway, the results indicate that the mechanisms whereby PDX-1 is reduced from the 
nucleus differ. Nevertheless, our results suggest that under chronic hyperglycemia,  
IRE1α-JNK signaling may decrease insulin gene transcription via phosphorylation of 
PDX-1. PDX-1 phosphorylation has been reported to cause its export from the nucleus as 
well as to interfere with PDX-1 binding to the insulin promoter [114, 115]. Our data 




Figure 3.3. Chronic high glucose, but not experimental ER stress inducers, cause intense activation of 
the IRE1-JNK pathway and strong serine phosphorylation of PDX-1 by JNK. 
A) INS-1 832/13 cells were incubated in 5 mM glucose RPMI or 16.7 mM glucose RPMI for 72 hours. 
PDX-1 was immunoprecipitated (IP) using total cell lysates. IP products were immunoblotted (IB) with 
anti-PDX-1 antibody and anti-phospho-serine antibody. Input protein was also run as a control and 
immunoblotted with anti-phospho-serine antibody. 
 
B) INS-1 832/13 cells were pretreated with 5 mM glucose for 20 hours, and then with 2.5 mM glucose for 
1 hour. The cells were then stimulated with KRB buffer containing 5 mM or 16.7 mM glucose or 5 mM 
glucose and thapsigargin (1 µM) for 3 hours. PDX-1 was immunoprecipitated (IP) using total cell lysates. 
IP products were immunoblotted with anti-PDX-1 antibody and anti-phospho-serine antibody. Input protein 





















Chronic high glucose causes ER stress and reduces insulin gene expression in 
pancreatic β-cells 
Our work has shown that the IRE1α ER stress signaling pathway is involved in 
the molecular mechanisms of the reduction of PDX-1 from the nucleus of pancreatic β-
cells. However, this alone cannot account for the dramatic reduction in insulin mRNA 
observed during chronic exposure to high glucose levels. Additionally, treatment with 
thapsigargin has been shown to decrease insulin mRNA without affecting the insulin 
gene promoter [113], suggesting that a mechanism independent of PDX-1 inactivation is 
responsible for the reduction of insulin mRNA. Thus, our study continued by exploring 
another mechanism by which ER stress and IRE1α signaling may impact insulin gene 
expression. To investigate the effect of chronic high-glucose treatment on expression 
levels of insulin and ER stress response genes, we treated INS-1 832/13 cells and primary 
mouse islets with increasing concentrations of glucose for 24 and 72 hours, then 
measured expression levels of insulin 1 and insulin 2 gene expression, as well as 
expression of several well-known markers of ER stress. 
After 24 hours, both insulin 1 and insulin 2 gene expression increased with 
increasing glucose. Expression levels of spliced Xbp-1 and Ero1α, ER stress markers, 
also increased with glucose concentration. The expression of Chop, an ER stress marker 
of apoptosis remained the same, suggesting that chronic glucose treatment causes mild 
ER stress, but not cell death (Figure 3.4A). Seventy-two hour treatment with high glucose 
caused a dramatic reduction in both Insulin 1 and Insulin 2 gene expression, an indication 
of glucose toxicity (Figure 3.4B). We also observed a decrease in Xbp-1 splicing and  
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Figure 3.4. Chronic high-glucose treatment causes ER stress in islets and insulinoma cells, resulting 
in a reduction in insulin gene expression. 
A) Islets pooled from 6 mice were treated with 5 mM, 11 mM, or 16.7 mM glucose for 24 or 72 hours. 
Expression levels of Ero1α, Chop, spliced and total Xbp-1 were measured by real- time PCR (n = 2).  
 
B) Islets pooled from 6 mice were treated with 5 mM, 11 mM, or 16.7 mM glucose for 24 or 72 hours. 
Expression levels of insulin 1 and insulin 2 were measured by real time PCR (n = 2).  
 
C) INS-1 832/13 cells were pretreated for 12 hours with 5 mM glucose, then treated with 5 mM, 11 mM, or 
16.7 mM glucose for 72 hours. Expression levels of insulin 1, insulin 2, and spliced Xbp-1 were measured 
by real time PCR (n = 3; values are mean±SEM).  
 
D) INS-1 832/13 cells were pretreated for 12 hours with 5 mM glucose, then treated with 5 mM, 11 mM, or 
16.7 mM glucose for 72 hours. Total IRE1α, phosphorylated IRE1α, and actin were measured by 
immunoblot. 
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other ER stress markers in the islets after 72 hour treatment with 16.7 mM glucose 
(Figure 3.4A), and with both 11 mM and 16.7 mM in INS-1 832/13 cells (Figure 3.4C). 
This decrease in Xbp-1 splicing directly correlated with the decrease in insulin 1 and 
insulin 2 gene expression. However, we observed that phosphorylation of Ire1α increased 
as glucose concentration increased, and was much stronger after 72 hours of treatment, 
despite the reduction in XBP-1 splicing (Figure 3.4D). 
IRE1α overexpression correlates with reduced insulin mRNA 
Our results suggested that chronic high glucose activates an Xbp-1 independent 
Ire1α signaling cascade. The strong activation of Ire1α, combined with the loss of Xbp-1 
splicing during chronic high-glucose treatment, led us to hypothesize that IRE1α itself 
may have a direct function in the degradation of insulin mRNA. To test this hypothesis, 
we transfected COS-7 cells with mouse insulin 2 expression plasmid, then transfected 
wild-type human IRE1α expression plasmid or a kinase/endoribonuclease inactive 
dominant-negative mutant K599A IRE1α expression plasmid into these cells, then 
measured insulin gene expression (Figure 3.5A). We observed a reduction in insulin 2 
mRNA in cells overexpressing wild-type IRE1α, but not in cells overexpressing mutant 
K599A IRE1α or the pcDNA3 vector control. 
We also transfected either wild-type human IRE1α or K599A IRE1α expression 
plasmids into INS-1 832/13 cells and measured endogenous insulin 1 and insulin 2 
mRNA expression (Figure 3.5B). We found downregulation of both insulin 1 and insulin 
2 gene expression only in cells overexpressing wild-type IRE1α.  
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Figure 3.5. Overexpression of IRE1α correlates with reduced Insulin mRNA in cultured cells. 
A) COS-7 cells were transfected with mouse insulin 2 and cultured for 24 hours. Cells were then split into 
3 plates and transfected again with wild-type human Ire1α; IRE1α WT, a kinase/endoribonuclease inactive 
mutant human Ire1α; IRE1α KA; or pcDNA3 control. They were then cultured for 24 hours. Protein and 
RNA were collected from the same plates. Total IRE1α, phosphorylated IRE1α, and actin were measured 
by immunoblot. Expression levels of human IRE1α and mouse Insulin 2 were measured by real time PCR 
(n = 3; values are mean±SEM).  
 
B) INS-1 832/13 cells were transfected with human IRE1α WT or pcDNA3 control and cultured for 24 
hours. Expression levels of human IRE1α, endogenous rat insulin 1, insulin 2, and glucose transporter 2 
(glut 2) were measured by real time PCR (n = 3; values are mean±SEM).  
 
C) INS-1 832/13 cells were transfected with either pcDNA3 control or increasing concentrations of human 
IRE1α WT and cultured for 24 hours. Expression levels of human IRE1α, endogenous rat Insulin 1, Insulin 
2, and glucose transporter 2 (glut 2) were measured by real-time PCR (n = 3; values are mean±SEM). 
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To study the correlation between IRE1α expression levels and insulin gene 
expression, we expressed increasing amounts of wild-type IRE1α in INS-1 832/13 cells 
and measured expression levels of insulin. The results indicated a dose-dependent 
response to the amount of IRE1α expressed and the fold reduction in endogenous insulin 
mRNA (Figure 3.5C). Taken together, these data show a firm correlation between strong 
activation of IRE1α and the reduction of insulin mRNA independent of glucose 
concentration. 
Inhibition of IRE1α activation by a dominant negative mutant blocks both high 
glucose induced and thapsigargin induced insulin mRNA degradation 
To test the hypothesis that IRE1α is directly involved in the reduction of insulin 
mRNA upon exposure to chronic high glucose, we generated INS-1 832/13 cell lines 
expressing the dominant-negative mutant K599A IRE1α, using a lentivirus-based 
doxycycline-mediated induction system. We induced expression of K599A IRE1α or 
empty vector control in INS-1 832/13 cells, then challenged them with increasing 
concentrations of glucose for 72 hours (Figure 3.6A). As compared to the INS-1 832/13 
control cells, cells stably expressing the dominant-negative mutant K599A IRE1α 
resisted the high glucose-induced reduction in insulin mRNA and had higher gene 
expression for both insulin 1 and insulin 2. Thapsigargin, a chemical ER stress inducer, 
causes a significant decrease in the transcript levels of insulin 1 and insulin 2, while 
insulin promoter activity remains unaffected [113]. To determine whether IRE1α is 
responsible for this chemically induced ER stress decrease in insulin mRNA expression, 




Figure 3.6.  Cells expressing mutant IRE1α resist both chemical- and glucose-induced Insulin mRNA 
degradation. 
A) pTetRINS-1832/13 cells (control) and pTetRINS-1832/13IRE1αKA cells (stably expressing 
tetracycline-responsive K599A mutant IRE1α) were treated with doxycycline for 24 hours with 5 mM 
glucose to induce mutant IRE1α. Cells were then treated with 5 mM, 11 mM, or 16.7 mM glucose with 
doxycycline for 72 hours. Degradation of mRNA was assessed by measuring the expression of insulin 1 
and insulin 2 by real-time PCR (n = 3; values are mean±SEM).  
 
B) pTetRINS-1 832/13 cells (control) and pTetRINS-1832/13IRE1αKA cells (stably expressing 
tetracycline-responsive K599A mutant IRE1α) were treated with doxycycline for 24 hours to induce mutant 
IRE1α. mRNA transcription was attenuated by treating cells with 100 µg/mL actinomycin D for 1 hour. To 
induce degradation of insulin mRNA, 1 µM thapsigargin was added to the medium for 0, 1, 3 and 5 hours. 
mRNA degradation was assessed by measuring expression of insulin 1 and insulin 2 by real-time PCR (n = 






thapsigargin to induce insulin 1 and insulin 2 mRNA degradation. Cells expressing the 
dominant-negative mutant K599A IRE1α resisted the thapsigargin-induced decrease in 
both insulin 1 and insulin 2 gene transcripts observed in control cells (Figure 3.6B). 
Islets from mice heterozygous for IRE1α are resistant to high-glucose-mediated 
reduction in insulin mRNA expression 
We observed that cells in which strong activation of IRE1α was partially blocked 
by use of a mutant form of IRE1α were more resistant than control cells to the glucotoxic 
effects of chronic high glucose on insulin gene expression. We then tested whether islets 
from mice heterozygous for IRE1α are also more resistant to chronic high glucose. We 
treated islets from mice that were heterozygous for IRE1α or islets from their wild-type 
littermates with 16.7 mM glucose for 72 hours, then measured insulin 1 and insulin 2 
gene expression and Xbp-1 splicing (Fig. 3.7). Heterozygous mouse islets were more 
resistant to the glucotoxic effects of chronic high glucose exposure, in that they had 
higher insulin 1 and insulin 2 gene expression than did their wild-type littermate controls. 
However, splicing of Xbp-1 was lower in the IRE1α heterozygotes, suggesting that these 
mice were also more resistant to ER stress induced by chronic high glucose. These results 
suggest that IRE1α acts directly in the reduction of insulin mRNA under chronic ER 
stress conditions, and that blocking the activation of IRE1α under these conditions can 






Figure 3.7.  IRE1α heterozygous islets resist the negative effects of chronic high glucose. 
 
IRE1α WT or IRE1α heterozygous mouse islets were treated with 16.7 mM glucose for 72 hours. 



















Our results demonstrate a genetic and biochemical linkage between ER stress 
signaling and reduction in insulin mRNA expression in pancreatic β-cells under chronic 
high glucose conditions. We propose that IRE1α hyperactivation by chronic high glucose 
results in selective degradation of insulin mRNA, leading to glucose toxicity. It has been 
shown that insulin mRNA degrades rapidly under ER stress conditions in pancreatic β-
cells[113]. However, the precise mechanism whereby IRE1-mediated insulin mRNA 
degradation occurs is unclear. The reduction of insulin mRNA under ER stress conditions 
may be initiated by direct endonucleolytic cleavage by the nuclease domain of IRE1, 
ultimately leading to degradation of the insulin message. Alternatively, IRE1 may 
function in the activation or recruitment of additional ribonucleases that can degrade 
insulin messages. It is also possible that IRE1 signaling may somehow initiate insulin 
gene-specific transcriptional stalling. Regardless of the precise mechanism, our data show 
that IRE1α, a central component of ER stress signaling, has an essential function in the 
reduction of insulin mRNA. 
Chronically high levels of glucose also cause oxidative stress, leading to 
activation of c-Jun N-terminal protein kinase (JNK). This JNK activation suppresses 
PDX-1 binding to the insulin promoter and reduces insulin gene expression [24]. We 
have shown previously that in mammalian cells, ER stress signaling activates JNK 
through IRE1 [53]. Our data suggest that chronic high glucose causes ER stress induced 
activation of IRE1α-JNK signaling. Thus, hyperactivation of IRE1α by chronic high 
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glucose may also suppress insulin gene expression partially through JNK-mediated PDX-
1 inactivation leading to reduced transcription of the insulin gene. 
Numerous studies have implicated PDX-1 and MafA, two transcription factors 
that are important for insulin gene transcription, in the defective insulin gene expression 
in β-cells caused by chronic exposure to supraphysiologic concentrations of glucose[105, 
106, 116-119]. Chronic exposure of β-cells to excess glucose decreases PDX-1 gene 
expression and MafA protein expression, leading to the suppression of insulin gene 
expression. Our current results suggest that mRNA degradation is an additional 
contributor to the reduction in insulin gene expression observed upon chronic exposure to 
high glucose. All of these effects may act synergistically to decrease insulin mRNA. 
Our work demonstrates that two distinct activities are elicited by high-glucose-
induced activation of IRE1α in pancreatic β-cells. IRE1α can be activated in β-cells by 
overexpressing insulin; and moreover, the level of activation positively correlates with 
the amount of insulin (Lipson and Urano, unpublished observations). We therefore 
believe that exposure of β-cells to high glucose levels causes ER stress due to an 
increased load of insulin translation into the ER. In earlier studies, we found that IRE1α 
signaling, activated by acute exposure to high glucose, enhances proinsulin biosynthesis 
[98]. In contrast, chronic exposure of β-cells to high glucose causes hyperactivation of 
IRE1α, leading to the degradation of insulin mRNA. Thus, we propose that the duration 
of exposure to high glucose, and therefore, the relative load of translocating insulin, are 
the critical determinants of the activity of IRE1α. 
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High glucose exposure causes ER stress and upregulation of ER folding 
machinery. Insulin mRNA expression increases, but only to a point. This point may 
represent the time when the burden that the translocating insulin is placing on the ER 
exceeds the ER processing capacity. In this scenario, the “classical” solution would be to 
activate Xbp-1 splicing and synthesize more ER folding machinery. However, this 
upregulation of ER stress-response proteins may add to the burden of the already 
overloaded ER. The rapid degradation of insulin mRNA could provide immediate relief 
to the ER and free the translocation machinery. Thus, this mechanism may be an essential 
element in the adaptation of β-cells to chronic hyperglycemia. This rapid mRNA 
degradation, combined with the IRE1α-JNK induced inactivation of PDX-1, may act 
synergistically to reduce insulin gene expression.  
Chronic ER stress has recently been defined as any persistent (on the order of 
days to years) stress that requires long term adjustments in cellular function [20]. For 
cells to survive under a chronic ER stress condition like prolonged hyperglycemia, they 
must have a mechanism by which ER stress can be continuously tolerated. A small 
number of cells may die, but the majority of cells must survive and adapt to the stressful 
stimulus, which, in this case, is chronic exposure to high glucose levels. This adaptation 
may be crucial for the maintenance of β-cell homeostasis and may, in part, explain why 
the β-cells of Type 2 diabetic patients with chronic hyperglycemia stop producing insulin 
without simply undergoing apoptosis. 
The IRE1-mediated mRNA decay pathway may not, however, be limited to a 
stress-response function. In other types of secretory cells, this mechanism of selective 
 79 
degradation of mRNAs by IRE1 may be an effective way to quickly control levels of 
secretory proteins. In addition to transducing the ER stress response, secretory cells may 
also activate IRE1 in response to various cellular stimuli, allowing adaptation to rapidly 
changing physiological conditions. In β-cells, it remains to be seen whether these 
reductive effects of IRE1α on insulin mRNA are actually important for insulin protein 
biogenesis, which is regulated at many levels. Modulation of levels of its message is 
certainly one place for regulation. If the load of insulin folding and processing is 
exceeding the capacity of the ER, then rapid reduction of insulin mRNA would preserve 
ER homeostasis and help ensure that the insulin already inside the ER can be properly 
folded and secreted. This mechanism may also be involved in suppression of the 
autoimmune response by reducing the amounts of misfolded insulin, which could be a 
source of “neo-autoantigens.” 
Based on recent studies and the results reported here, we suggest that in β-cells 
IRE1α selectively degrades insulin, the most prevalent ER-targeted mRNA, under 
adverse conditions. This may be part of a protective adaptation that β-cells have uniquely 
acquired to protect themselves from death caused by the chronic and high workload 
placed on the ER under prolonged hyperglycemic and/or hyperinsulinemic conditions. 
This, combined with subsequent upregulation of ER stress response genes, may function 






DISCUSSION AND PERSPECTIVES 
 
 Diabetes is quickly reaching epidemic proportions worldwide, and its 
heterogeneous nature has made determining underlying causes somewhat difficult. When 
we began our studies, there existed some genetic evidence implicating ER stress and 
defective ER stress signaling in the development of rare forms of experimental and 
clinical diabetes. This evidence suggested that activation of certain ER stress signaling 
pathways may be critical to the normal function of insulin-secreting β-cells, and that β-
cells may also be especially sensitive to the adverse effects of perturbed ER function. The 
work presented in this dissertation was undertaken to reveal physiological, as well as 
pathological roles, of ER stress signaling in pancreatic β-cells. This information furthers 
our understanding of the normal function of pancreatic β-cells and also sheds light on 
processes involved in insulin biosynthesis and β-cell homeostasis. 
 In Chapter II we presented evidence that activation of IRE1α by high glucose 
treatment has a beneficial effect in β-cells and aids in the proper folding of proinsulin 
inside the ER. Glucose exposure stimulates insulin biosynthesis[10].  Here we present a 
model whereby glucose-mediated stimulation of proinsulin biosynthesis promotes some 
ER stress because it imposes a load on the protein folding and processing machinery of 
the ER.  This results in activation of IRE1α and a slight upregulation of a unique subset 
of downstream components of ER stress signaling like ERO1α and WFS1. Unexpectedly, 
this process occurs independently of XBP-1 splicing. Additionally, the mechanism of 
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IRE1α activation by transient high glucose appears to differ from that of activation by 
chemical ER stress inducers in regard to BiP dissociation. IRE1 mediated cleavage of 
XBP-1 mRNA depends on its kinase activity—only wild-type kinase active IRE1 can 
cleave its mRNA substrate.  Upon ER stress, IRE1 dimerizes, which then facilitates 
trans-autophosphorylation and subsequent kinase activation. The coupling of 
phosphorylation to endoribonucleolytic cleavage, however, has remained unknown.  
 In 2003, researchers found a hint to this mechanism when they attempted to 
inhibit IRE1’s kinase activity via a mutation in the ATP binding pocket to allow the 
binding of a bulky kinase inhibitor[120]. Instead of inhibiting IRE1’s endoribonuclease 
activity, however, the inhibitor actually stimulated it. This finding, along with the recent 
elucidation of the crystal structure of IRE1 [46, 121], reveals that the activation of the 
endoribonuclease domain is triggered by a conformational change in the kinase domain, 
promoted by trans-autophosphorylation of a kinase activation loop.  
These and other studies have also indicated that it is possible that BiP binding to 
IRE1 negatively regulates XBP-1 splicing. IRE1 endoribonuclease activity is attenuated 
in mutants where BiP dissociation is impaired [122]. Also, mutations in IRE1 that abolish 
the BiP binding site render IRE1 hypersensitive to stress, [45] further supporting the idea 
that BiP binding to IRE1 may serve to dampen activation of downstream targets of IRE1 
(i.e.XBP-1). Lastly, IRE1 mutants unable to dissociate from BiP can still sense stress 
caused by unfolded proteins [46]. These previous findings support our observation that 
BiP is still bound to IRE1 under transient high glucose treatment, and under these 
conditions we see no XBP-1 splicing. BiP association with IRE1 may inhibit the 
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conformational change required to activate the nuclease domain, yet still activate an 
XBP-1 independent signaling pathway.  The mild ER stress caused by glucose-mediated 
stimulation of proinsulin biosynthesis may not be severe enough to cause BiP 
dissociation and subsequent XBP-1 splicing, although IRE1’s interaction with the 
unfolded proinsulin may still induce dimerization and trans-autophosphorylation.  
Although BiP binding and release appears to not be a requirement for control of 
IRE1 activity, ours and others’ work indicates it likely provides a regulatory role under 
extreme activation conditions, when the pool of free BiP in the ER lumen becomes 
severely depleted. These conditions may include non-physiological experimental 
conditions using chemical ER stress inducers like tunicamycin, or upon prolonged UPR 
induction (i.e. as in Chapter III with chronic high glucose induced ER stress). BiP release 
under such conditions could serve to induce a conformational change that allows 
activation of IRE1’s nuclease domain. Conversely, BiP binding may dampen activation 
of IRE1 under conditions of mild unfolded protein accumulation (i.e., transient high 
glucose-mediated stimulation of proinsulin biosynthesis) through inhibition of the 
conformational change required for nuclease domain activation. 
IRE1α phosphorylation and mild upregulation of a subset of ER stress response 
genes by transient high glucose, without the accompanying XBP-1 splicing suggests 
several possibilities. IRE1α phosphorylation and mild upregulation of a subset of ER 
stress response genes by transient high glucose may, in fact, cause a very small amount of 
XBP-1 splicing, undetectable by our methods, but sufficient enough to cause the very 
mild upregulation of certain ER response genes. Alternatively, under mild ER stress 
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conditions, the unspliced XBP-1 mRNA may be preferentially translated, and may be 
capable of weakly activating ER stress response genes promoters. Another idea is that 
IRE1α may have an additional role in β-cells. One emerging possibility comes from 
recent evidence indicating that protein folding, ER stress, and production of reactive 
oxygen species (ROS) are closely coupled to one another [92].  Proper protein folding 
and disulfide bond formation depends on the redox status inside the ER lumen. 
Mispairing of cysteine residues and inappropriate disulfide bond formation prevents 
proteins like insulin (which requires 3 disulfide bonds) from attaining their native 
conformation.  Approximately 25% of the ROS generated in a cell may result from 
formation of disulfide bond formation in the ER, and thus proteins that have multiple 
disulfide bonds are expected to be more prone to generating ROS [123]. Because β-cells 
must fold a lot of insulin, they may also be especially sensitive to perturbations of the 
oxidizing ER environment. Activity of the oxidoreductase ERO1α is tightly coupled with 
the protein-folding load in the ER [92]. Thus, it is possible that IRE1α may play an 
important role in the maintenance of the oxidizing environment of the ER, perhaps 
through upregulation of a variety of different redox enzymes, like ERO1, and other small 
molecule oxidants.  Alterations in redox status and generation of ROS through proinsulin 
disulfide bond formation could directly affect β-cell ER homeostasis and proinsulin 
folding. Elucidating the relationship between ER stress and oxidative protein folding is 
indeed a significant area for future research. 
In both Chapter II and III we show strong evidence that IRE1α phosphorylation is 
induced by exposure to high glucose. Our phospho-IRE1α antibody recognizes a specific 
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motif, (VGRH(pS)FSRRSG) which is conserved from yeast to humans. In pancreatic β-
cells, this site is phosphorylated in response to treatment with many different types of ER 
stress inducers, including tunicamycin, thapsigargin, and high glucose (which requires 
glucose metabolism). However, it is likely that other phosphorylation sites exist in the 
kinase activation loop of IRE1α. It is possible that combinations of phosphorylation of 
these sites in response to different stimuli may have different biological functions, or may 
even influence the dimerization/oligomerization state of IRE1. Indeed, there is some 
disagreement in the field as to whether IRE1 can form higher order oligomers, or whether 
it strictly exists as a dimer in its active state. Emerging evidence points to yes, that dimers 
of IRE1 may actually be tethered by unfolded proteins forming active oligomers, and that 
the biological functions and signaling pathways in these various states may differ [46, 
124]. This is an intriguing possibility that requires further investigation.  
Our study demonstrates both a physiological and pathological role for Ire1α 
signaling in pancreatic β-cells (Figure 4.1). IRE1 plays an essential role in the positive 
regulation of insulin biosynthesis, which indicates that physiological ER stress has a 
beneficial effect in pancreatic β-cells. We therefore add β-cells to a growing list of 
secretory cells (plasma cells [51, 52], T-cells [125], trophoblast cells [126]) that utilize 
ER stress signaling pathways for beneficial processes, differentiation, and normal day-to-
day function. We also identify glucose as a physiological activator of ER stress signaling 
and recommend its use for future studies of the UPR and perhaps unknown signaling 




Figure 4.1. Model of physiological and pathological IRE1 activation in pancreatic β-cells 
In a healthy individual, consuming food causes an acute increase in blood glucose concentration. This 
results in insulin secretion from the β-cells in the pancreas and stimulates proinsulin biosynthesis in the ER. 
Here we present a model whereby glucose-mediated stimulation of insulin biosynthesis promotes 
physiological ER stress because it imposes a load of insulin on the protein folding and processing 
machinery of the ER. This has a beneficial effect in β-cells because it results in activation of IRE1 and a 
slight upregulation of a unique subset of downstream components of ER stress signaling like WFS1, ERO1 
and PDI, which aid in the oxidation and folding of the insulin molecule. 
 
In a diabetic individual, hyperglycemia usually occurs due to resistance to the actions of insulin. In this 
model, chronic hyperglycemia puts severe stress on the cell in a futile attempt to enhance insulin 
biosynthesis and secretion. The ER of the β-cell may become unable to process and fold the large amounts 
of insulin mRNA targeted to the ER. Under these pathological ER stress conditions, the ribonuclease 
activity of IRE1 may now selectively target insulin mRNA for degradation to reduce the workload on the 
stressed ER of the exhausted β-cell. Our model suggests that this may be an adaptive response designed to 
preserve the homeostasis of the β-cell. Unfortunately this preservation occurs at the expense of insulin 
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However, we also show that prolonged activation of IRE1 signaling negatively 
affects β-cells, in that it results in a decrease in insulin gene expression. Our work 
implicates chronic ER stress in the mechanisms of glucose toxicity, however, we provide 
evidence that the IRE1α mediated decrease in insulin mRNA may be an adaptive 
response β-cells have acquired to protect themselves from ER stress induced death. We 
also believe our findings further contribute to the understanding of the complex 
mechanisms of β-cell dysfunction in the progression to Type 2 diabetes (T2D). 
The normal pancreatic β-cell’s response to a chronic caloric excess and obesity-
associated insulin resistance is hypersecretion of insulin in order to maintain normal 
blood sugar levels (β-cell compensation). It seems likely that IRE1α is active in a 
physiological role under these conditions, helping to maintain favorable conditions in the 
ER that allows for the increase in insulin biosynthesis required to keep up with the 
hypersecretion.  Studies of people that develop T2D show a rise in insulin levels in the 
normoglycemic and prediabetes phases that keep blood sugar levels near normal, despite 
the insulin resistance (β-cell compensation). T2D only develops in subjects that are 
unable to sustain the β-cell compensatory response (β-cell failure) and this is 
accompanied by a decline in insulin levels.   
Compensation fails in subjects that have “susceptible”, as opposed to “robust”, 
islets. Compensation involves expansion of β-cell mass, enhanced insulin biosynthesis, 
and increased responsiveness of nutrient-secretion coupling [127]. Insulin biosynthesis is 
known to be regulated by acute changes in nutrient availability [87], but very little is 
known about longer-term adaptations in transcriptional/translational regulation of insulin 
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production to situations such as chronic overnutrition. Our work suggests ER stress 
signaling via IRE1α enhanced insulin biosynthesis may be important in the process of β-
cell compensation.  
β-cell failure occurs in islets that are undergoing the processes of compensation 
for insulin resistance. One model of β-cell failure suggests either one, or a small number, 
of β-cell defects act as the weak link in the processes of β-cell compensation that initiate 
β-cell dysfunction [77]. The likely mechanisms of early β-cell demise are numerous,  
including mitochondrial dysfunction, oxidative stress, ER stress, dysfunctional 
triglyceride/FFA (TG/FFA) cycling, and glucolipotoxicity. β-cell compensation may 
progress to β-cell failure in subjects who are genetically susceptible to ER stress or have 
a defect in ER stress signaling. One intriguing possibility our work suggests is that 
chronic activation of the IRE1α signaling pathway initiates a β-cell protective response. 
During the switch from compensation to failure, the insulin resistance worsens, 
hyperglycemia occurs, and the ER of the β-cells can no longer keep up with the large 
amounts of insulin mRNA targeted to the ER to enhance insulin biosynthesis and 
secretion. In this scenario, the ribonuclease activity of IRE1α may now selectively target 
insulin mRNA for degradation to reduce the workload on the stressed ER of the 
exhausted β-cell. This may preserve the homeostasis of the β-cell, but at the expense of 
insulin production and secretion.  
For cells to survive under chronic ER stress conditions like prolonged 
hyperglycemia or hyperproduction and secretion of insulin, they must have a mechanism 
by which ER stress can be continuously tolerated. A small number of cells may die, but 
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the majority of cells must survive and adapt to the stressful stimulus [20]. In one human 
study, T2D subjects had a 41% loss of β-cell volume compared with weight-matched 
controls. Furthermore, the decreased volume was not a consequence of reduced β-cell 
proliferation but was associated with increased β-cell death by apoptosis [4]. This 
adaptation may be crucial for the preservation of β-cells and may, in part, explain why 
the remaining 60% of β-cells of Type 2 diabetic patients with chronic hyperglycemia stop 
producing insulin without simply undergoing apoptosis. 
What about the β-cells that do undergo apoptosis? It has been suggested that two 
signaling components of ER stress, IRE1-JNK, and CHOP, have important roles in β-cell 
death mediated by ER stress. It has been shown that in the presence of chronic ER stress, 
IRE1 activates JNK through ASK1 and elicits apoptosis [53, 72]. This pathway may 
block the functions of the anti-apoptotic BCL2 family members Bcl2 and Bcl-XL by 
phosphorylating them, thus causing apoptosis in β-cells. Also, the IRE1-JNK pathway 
has been shown to enhance the functions of two pro-apoptotic factors, Bax and Bak, and 
can lead to apoptosis in some cell types [73]. Although some studies have indicated that 
JNK activation contributes to cytokine-induced β-cell death [128], the function of ER 
stress–mediated JNK activation in the death of β-cells has not been studied extensively 
and must be defined. Nevertheless, our findings in Chapter II indicate that the IRE1-JNK 
pathway is activated by chronic high glucose treatment. Susceptible β-cells that cannot 
reduce their ER workload via insulin mRNA degradation may undergo apoptosis via the 
IRE1-JNK pathway. Our work also suggests that a transient increase in insulin 
biosynthesis activates IRE1 signaling in β-cells and mildly upregulates the pro-apoptotic 
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factor CHOP. Thus, a prolonged increase in insulin biosynthesis, such as what occurs in 
patients with insulin resistance, may strongly upregulate CHOP and elicit apoptosis in 
this manner.  
Much of our work has focused on the importance of ER stress in the pathogenesis 
of Type 2 diabetes and rare forms of Type 1 diabetes such as Wolfram syndrome. 
However, ER stress-mediated β-cell death may also contribute to the pathogenesis of 
autoimmune diabetes. Since the baseline level of ER stress is high in pancreatic β-cells, it 
is possible that a slight additional increase in ER stress by environmental or genetic 
factors leads to β-cell death in patients who are genetically susceptible to ER stress. β-
cells dying as a consequence of a high level of ER stress may contain proteins with 
abnormal conformations (i.e., misfolded proteins). The engulfment of ER stress-induced 
apoptotic β-cells by dendritic cells in the islets may stimulate the maturation of β-cell-
reactive T-cells in draining lymph nodes and lead to T-cell-mediated autoimmune 
destruction by “neo-autoantigens” derived from misfolded proteins [129]. 
Our work, and recent work from other labs, suggests that IRE1α may be an 
attractive therapeutic target for the treatment of people with diabetes. Recent experiments 
show a single missense mutation in the ATP-binding pocket of mouse IRE1α’s kinase 
domain sensitizes it to the ATP-competitive inhibitor 1NM-PP1, and subordinates its 
RNase activity to the drug. Engagement of the drug-sensitized IRE1α kinase in this 
manner protects cells against ER stress induced cell death [130]. Thus kinase inhibitors of 
IRE1α may be useful for both preventing degradation of insulin mRNA, and altering the 
apoptotic outcome to ER stress, and could possibly be developed into drugs to treat ER 
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stress-related diseases. However, our work indicates that extreme caution must be taken if 
attempting to regulate IRE1α signaling; although mild activation of IRE1 has a beneficial 
effect on pancreatic β-cells, strong activation of IRE1 has a harmful effect on pancreatic 
β-cells, and could reduce insulin production in our body.  The ideal drug to enhance 
insulin biosynthesis, and perhaps, aid or extend the β-cell compensation stage, would 
cause only mild activation of IRE1. If degradation of insulin mRNA is, in fact, a 
preservation attempt, then inhibiting IRE1 activity under chronic hyperglycemia 
conditions may not be useful at all, as it may initiate apoptosis if the ER becomes 
overwhelmed with insulin processing.  Our work indicates that an IRE1 “inhibitor” drug 
may have the best effect after the insulin resistance has been controlled, to try to coax β-
cells into producing insulin again, or in combination with another drug that helps increase 
peripheral cells’ sensitivity to insulin. The “two-toned” nature of IRE1α activation, while 
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